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Diffuse Large B-cell Lymphoma (DLBCL) is the most common subtype of lymphoma. 
Despite a cure rate of 40% with standard R-CHOP therapy, patients that refract or relapse 
are subject to a dismal prognosis. Cases of DLBCL can be classified by their molecular 
expression phenotype, with the GCB-like subtype aligning with the profile of a germinal 
center B-cell and the ABC-like subtype aligning to that of an activated B-cell. Aggressive 
disease is often characterized by high levels of B-cell Receptor (BCR) signaling. This 
pathway engages downstream kinases responsible for stimulating proliferation and 
survival that play a key role under the normal circumstances of B-cell development. A 
comprehensive study aimed at delineating sources of inhibitor insensitivity within the BCR 
signaling pathway was conducted in order to identify novel drivers of disease and improve 
clinical outcome. A cohort of 39 aggressive lymphoma cell lines was assayed for sensitivity 
to Ibrutinib, a BTK inhibitor, and Umbralisib, a PI3Kδ inhibitor. Combined with intracellular 
phosphoflow measurements, these results revealed that higher levels of proximal BCR 
kinase (SYK, LYN, BTK, BLNK) and AKT (downstream of PI3K) signaling were highly 
linked and predictive of inhibitor insensitivity. Simultaneous inhibition of these pathways 
with Ibrutinib and Umbralisib consequently revealed a synergistic relationship. Following 
these results, a DNA copy number analysis of 673 DLBCL patient profiles was performed 
	 iii	
alongside 249 matching gene expression profiles to uncover the genomic drivers 
responsible for higher signaling. These results identified an enrichment of genes with 
transcription factor activity within regions of significant DNA copy number gain and 
matching transcript gain. The TCF4 transcription factor was identified within the most 
significant gain peak at chromosome 18q21 and led to increased transcript and protein 
translation. TCF4 gain was associated with the aggressive ABC-like phenotype, poor 
survival, and increased transcription of key BCR signaling component targets, such as 
BLNK, BTK, PIK3CA (PI3Kα), and the IgM heavy chain constant region. Collectively, these 
results identified sources of inhibitor insensitivity within DLBCL, and TCF4 was 
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Chapter 1: Introduction 
1.1 Early B-cell Development 
B-lymphocytes and their antibodies are central elements of the adaptive immune 
system and serve to protect the body against an almost unlimited variety of pathogens. 
Defects in this complex developmental process can trigger autoimmunity, 
immunodeficiency, and malignancies. A greater understanding of early B-cell 
development has led researchers towards new insights and treatment options for these 
complications and continues to provide a crucial blueprint for proper characterization of 
the physiological landscape of B-cells. 
B-cell development begins in the bone marrow (BM). During embryonic life, the 
BM is seeded by hematopoietic precursor cells that have developed within the fetal liver1. 
Early B-cell development is defined by successive rearrangements of the immunoglobulin 
(Ig) gene segments facilitated by cytokine-induced activation of Terminal deoxynucleotidyl 
Transferase (TdT) and RAG-1/RAG-2 recombinase2. Rearrangements of the heavy chain 
VH, DH, and JH gene segments alongside the light chain VL-JL genes are required for the 
successful expression of the pre-B-cell Receptor (BCR) and eventually the mature BCR 
and define three primary developmental stages3 (Figure 1). Pro-B-cells rearrange the D 
and J segments of the heavy chain, which is followed by a second rearrangement joining 
an upstream V region to the rearranged DJ gene segment. Surrogate light chain segments 
(V-preB and O5) are manufactured alongside the fully rearranged heavy chain V(D)J 
segments and P-heavy chain constant region. Complete formation of the surface BCR with 
surrogate light chain segments opens entry into the next stage: pre-B-cell.  These cells 
undergo 1 or 2 cell divisions and rearrange gene segments encoding the light chain genes, 
N and O4. If the initial N light change rearrangements form nonproductive segments, a 
process called light chain rescue initiates rearrangement of the O light chain gene. If this 
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second attempt falls short, the cell fails to express a pre-BCR and undergoes apoptosis 
by neglect. Combing the successfully rearranged V(D)J, P-heavy chain, and light chain (N 
or O) gene segments allows for the expression of the IgM BCR isotype on the surface of 
the cell. Failed somatic recombination of the heavy chain and light chain genes results in 
nonproductive rearrangements that fail to code for a proper pre-BCR and ultimately lead 
to cell death via neglect of vital downstream pre-BCR survival signals5. Successfully 
rearranged cells with a surface pre-BCR are defined as immature B-cells. These cells 
migrate from the BM to the spleen, where they finalize development by differentiating into 
naïve, follicular, or marginal zone B-cells3. Naïve B-cells are ultimately destined for 
germinal center (GC) development and differentiation into memory B-cells or plasma cells 
if they develop surface BCRs with the highest affinity for presented antigen. 
 
Proper pre-BCR formation also depends on the expression of the adaptor signal 
transducers CD79A and CD79B (also known as IgD and IgE). The adaptor molecules 
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attach to the intracellular portion of the IgM surface molecule and transduce activation 
signals through their Immunoreceptor Tyrosine Activation Motif (ITAM) regions following 
autophosphorylation triggered by antigen binding or surface IgM crosslinking. Cells 
without these functional units fail to survive, highlighting the importance of the downstream 
survival signals they orchestrate. CD79A and CD79B signals are mediated through 
Bruton’s Tyrosine Kinase (BTK) and B-cell Linker Protein (BLNK) binding to their 
phosphorylated ITAM regions6–8. Another key function of the pre-BCR is serving as a 
screen for autoreactivity. B-cells are screened at several autoimmunity checkpoints (AICs) 
during development to measure the degree to which they recognize “self-antigen” via their 
pre-BCR9. B-cells that evade these check points can potentially differentiate and develop 
autoreactive antibodies, so stringent AICs are a vital protective mechanism. Hyperactive 
binding to surrounding self antigen triggers an overwhelming signal from the pre-BCR, 
resulting in apoptosis and negative selection of the autoreactive clone9,10. Proper pre-BCR 
expression also coordinates allelic exclusion by triggering the shut down of the enzymatic 
machinery responsible for heavy chain gene variant segment rearrangements11. Silencing 
the other heavy chain genes ensures that a B-cell only expresses a single isotype on its 
surface. Polyreactive B-cells that bypass allelic exclusion are subject to clonal deletion 
through anergy9. Immature B-cells with successfully rearranged surface BCR molecules 
migrate to the peripheral lymphoid organs in order to undergo clonal selection, BCR 
editing, and affinity maturation within GC follicles12. Secondary organs include the lymph 
nodes, Peyer’s Patches, tonsils, and appendix. B-cells pass through T-cell-rich areas 
during their migration, and when they encounter antigen and appropriate T-cell help they 






1.2 Germinal Center Development 
Germinal centers are peripheral lymphoid organs that facilitate the development of 
B-cell antigen recognition and differentiation (Figure 2)15. They are the sites where somatic 
hypermutation (SHM) of the genes encoding the immunoglobulin variable region occurs 
and where B-cells are selected for further differentiation based on their BCR antigen-
binding capabilities16. GCs are responsible for producing plasma cells, the final stage of 
B-cell differentiation, which secrete antibodies that bind to pathogen and designate it for 
immune destruction14. Another final product of B-cell development is the memory B-cell, 
which enters a quiescent existence until re-challenged by recognizable pathogen14. GCs 
are critical to the proper function of the immune system as a whole, but the dynamic and 
unique elements that they introduce to increase antibody binding efficiency make them 




The T-cell-dependent antibody response to exogenous antigen initiates GC 
formation in the follicles of peripheral lymphoid tissues18. Follicles mainly consist of naïve 
IgM+ or IgD+ surface BCR isotype B-cells and are separated by an interfollicular region 
that separates the B-cell and T-cell zones. After encountering exogenous antigen 
presented by dendritic cells, B-cells migrate to the interfollicular zone where they form 
long-lived interaction with antigen-specific T-cells19,20. This process occurs within the first 
24 hours after antigen exposure21. Following T-cell interaction, a subset of the selected B-
cells migrate to the medullary chords where they differentiate into short-lived plasmablasts 
that secrete antibodies that have low affinity for the invading pathogen but provide an 
immediate response22. Interestingly, it appears that the highest-affinity B-cells from this 
stage are selected for plasmablast differentiation, while those with weaker epitope binding 
are directed to the GC for affinity maturation and subsequent plasma cell and memory B-
cell differentiation if they are selected for23. Lastly, the interclonal competition for T-cell 
signals determines the highest affinity B-cells that will advance to the GC24. A higher 
number of BCR-antigen interactions selects for B-cells cells with high-affinity BCR 
molecules. Selected B-cells thus receive more survival and proliferation signals than 
competing clones with less BCR-antigen affinity.   
The GC can be histologically identified as quickly as 4 days after antigen exposure. 
At this time, the selected B-cells grow and differentiate into B-cell blasts that rapidly 
proliferate and populate the network of follicular dendritic cells (FDCs) at the center of the 
follicle14. The rapid proliferation displaces the IgM+ or IgD+ B-cells, resulting in the 
formation of the mantle zone around the GC13. After 5-6 days from initial antigen exposure, 
the rapid proliferation of B-cell blasts continues until day 7. At this stage, the GC has been 
fully established into two polarized microenvironments: the dark zone and the light zone14. 
The dark zone is named for its histological appearance and consists of densely populated, 
highly proliferative blast cells. Dark zone blast cells undergo SHM to improve the variable 
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regions of their surface BCR and are selected for binding affinity upon entry into the light 
zone. Recently, light zone entry has been found to be facilitated by a network of reticular 
cells that express CXC-chemokine ligand 12 (CXCL12), a morphologically-similar 
phenotype as the light zone FDCs25. These cells play a large role facilitating the migration 
from the dark zone to the light zone by establishing a gradient of CXCL12 originating in 
the light zone that attracts CXC-chemokine ligand 4 (CXCR4)-expressing dark zone 
centroblasts. In contrast to dark zones, light zones are more sparsely populated by 
developing B-cells and characterized by the presence of several cell types responsible for 
antigen affinity selection, including T-follicular helper cells (TFH), FDCs, and 
macrophages26. B-cells in the light zone are characterized as centrocytes that are smaller 
in size and not actively proliferating. A subset of centrocytes may eventually be selected 
for the final stages of plasma cell or memory B-cell differentiation, but the will often be re-
cycled back into the dark zone to further increase clonal BCR affinity13. Centrocytes 
designated for re-cyclic entry to the dark zone express CXC-chemokine ligand 5 (CXCR5), 
which is responsive to a CXC-chemokine ligand 15 (CXCL15) gradient produced in the 
dark zone27. 
The selection of centrocytes on the basis of antigen affinity is mainly facilitated by 
TFH cells28. Centrocytes capture antigen via the BCR, engulf and digest it, and present 
processed antigen on Major Histocompatibility (MHC) class II complexes to TFH cells. 
Higher BCR affinity leads to increased antigen capture and subsequently a higher density 
of peptide-MHC presentation. This results in a greater share of TFH cell stimulation, which 
in turn drives selection13,28. Recent work visualized the transient TFH cell interactions with 
centrocytes that allow for the selection of those cells with the highest MHC complex 
density12. Another hallmark study uncovered that centrocytes receiving the most TFH cell 
help undergo cyclic re-entry into the dark zone and are programmed to divide the greatest 
number of times, which inherently facilitates more SHM since the processes are intimately 
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linked29. This work illustrated a feed-forward loop in which the highest affinity centrocytes 
are repeatedly cycled back and forth between light and dark zones and dominate the 
lower-affinity B-cells participating in selection, owing to the original signal density they 
received from TFH cells. The exact signaling mechanism between TFH and B-cells 
remains unclear, but several early activation signatures were found to be enriched in 
centrocytes after TFH cell interaction, including those associated with the CD40, BCR, 
and Nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-kB) pathways28. 
Another key mechanism for increasing the selection of high affinity BCRs is antigen 
masking of FDCs by plasma cell that were generated earlier in the GC response30. This 
way, past levels of BCR affinity can be progressively improved upon, with the filter 
becoming more stringent over time due to antibody feedback. These processes coordinate 
and fine tune the production of antibodies capable of targeting invading pathogen for 
immune destruction, and the clonal evolution of B-cells remains one of the most powerful, 
if not volatile, mechanisms of the body’s defensive systems. 
 
1.3 Molecular Controls of the Germinal Center Reaction  
The GC reaction relies on precisely coordinated molecular control mechanisms. 
Transcriptional and epigenetic regulation of the GC reaction is vital to its success. Dark 
zone, light zone, and re-cycling cell physiologies are determined by fine molecular events 
that represent an important area of inquiry. 
 
1.3.1 MYC and NF-kB 
The GC reaction initially requires expression of the MYC transcription factor, but 
its expression quickly silenced after establishment by the B-cell lymphoma 6 (BCL6) 
transcription factor31. This opening burst of MYC expression presumably results in the 
stimulation of its targeted transcriptional programs, which increase proliferation, 
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metabolism, telomerase function, and Deoxyribose nucleic acid (DNA) replication32. 
Several findings indicate that MYC expression only resumes in light zone B-cell clones 
that are positively selected for cyclic re-entry into the dark zone for further proliferation 
and SHM. MYC positive (MYC+) GC B-cells were found to have similar gene expression 
profiles to light zone cells33. MYC+ cells were also actively proliferating and had a greater 
number of affinity-enhancing mutations than cells without MYC expression. Lastly, MYC 
expression was induced in light zone cells receiving T-cell help33. These results were 
validated when MYC inhibition resulted in the dissolution of established GCs31. These 
observations collectively revealed that MYC expression is required for GC establishment 
and indicates positive selection of a BCR clone and subsequent re-entry into the dark 
zone. 
Many parallels exist between increased MYC expression and the activity of the 
NF-kB heterodimer transcription factors. Like MYC, it is paradoxically silenced in highly-
proliferative dark zone B-cells, but NF-kB-associated gene signatures were identified in 
light zone B-cells28,31. Deletion of the NF-kB subunit RELA induced GC collapse and equal 
losses of dark zone and light zone cells34. These results suggested that REL was 
responsible for NF-kB establishment of a metabolic program that enabled antigen-
selected light zone B-cells to recirculate back to the dark zone. MYC and NF-kB gene 
expression signatures are mirrored throughout light zone cells, and NF-kB signatures are 
specifically enriched in MYC+ GC-bells, suggesting a strong association responsible for 
regulating cyclic re-entry into the dark zone from the light zone28,33. 
 
1.3.2 BCL6 
The BCL6 transcription factor is a key transcriptional repressor responsible for 
driving GC formation and maintanence35. Cells in the interfollicular zone that have 
successfully engaged antigen and T-cells are the first to express BCL636. Induction is 
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initiated by Interferon regulatory factor 8 (IRF8), Interferon regulatory factor 4 (IRF4), and 
the myocyte-specific enhancer factor 2 (MEF2B)37–39. Once induced, BCL6 autoregulates 
its own expression through repressive binding of its own promoter40. BCL6 promotes and 
modulates the GC reaction through inhibition of genes responsible for cell cycle arrest, 
apoptosis, and DNA damage response (so that SHM may occur without initiating 
apoptosis). Repressive BCL6 activity relies on binding target DNA motifs and recruiting 
class I and II histone deacetylase complexes41. The BCL6 program is directly responsible 
for preventing the premature B-cell activation or differentiation towards the exit of the GC42. 
Additionally, it was observed to be responsible for CXCR4 chemokine upregulation and 
integrin-dependent engagement of B-cells and T-cells, defining mechanics of the GC 
reaction36. BCL6-mediated repression of miR-155 leads to master upregulation of 
Activation induced cytidine deaminase (AID) and other GC-defining genes responsible for 
maintaining the reaction43. BCL6 mRNA was also detected in naïve B-cells absent protein, 
suggesting post-transcriptional regulation that could can be rapidly removed to promote 
upregulation for GC formation44. 
The exit from the GC reaction requires the abolishment of BCL6 expression, which 
releases its targets of repression. The IRF4 transcription factor plays a major role in this 
repression. Although IRF4 plays a role upregulating BCL6 during the GC initiation within 
a limited window, IRF4-mediated BCL6 repression occurs upon NF-kB activation following 
BCR, CD40, and Toll-like receptor (TLR) signaling39,45. Specifically, BCR signaling as a 
result of increased engagement leads to Mitogen-activated protein kinase (MAPK)-
mediated BCL6 phosphorylation and degradation46. The PR domain zinc finger protein 1 
(PRDM1) gene, which encodes the BLIMP1 protein, is the key BCL6 repression target 
that initiates differentiation once free from BCL6 regulation and serves as a final signal of 
developmental progrssion47. The success of the GC reaction is dependent on proper BCL6 
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expression, but dysregulation of this molecular regulator can lead to a lymphomagenesis 
mechanism in which cells are stuck in the GC phase continuously proliferating36.  
 
1.3.3 E-box Binding Proteins E2A and TCF4 (E2-2) 
The basic helix-loop-helix (bHLH) transcription factors Transcription factor 3 
(TCF3), also known as E2A, and Transcription factor 4 (TCF4), also known as E2-2, have 
recently been identified as central regulators of B-cells development, differentiation, and 
immunity48,49. Both are expressed at high levels in highly-proliferative dark zone B-cells50. 
TCF3 and TCF4 elicit target activation through homo or hetero dimerization and 
subsequent binding of target promoter and enhancer regions at the E-box 5’ CANNTG 3’ 
DNA motif51. The loss of either gene results in a reduced number of differentiated B-cells52. 
Incomplete loss is likely due to the cooperative nature of TCF3 and TCF4, which are 
capable of binding each other’s targets through homo dimerization or heterodimerization. 
Cooperative interaction with E1A binding protein P300 (p300), CREB-binding protein 
(CBP), and the promoter recognition Transcription factor II D (TFIID) allows this pair of 
transcription factors to activate a number of targets that regulate key mechanisms of B-
cell development53–55. 
Recent studies have confirmed the vital role that TCF3 and TCF4 play initiating B-
cell differentiation. Target genes with key roles promoting plasma cell differentiation 
include Inducible T-cell costimulator ligand (ICOSL), MEF2B, POU class 2 associating 
factor 1 (POU2AF1), Nei-like DNA glycosylase 1 (NEIL1), PRMD1, X-box binding protein 
1 (XBP1), and ELL associated factor 2 (EAF2), sometimes times induced through the 
regulation of distant enhancers48. The E-proteins induce and maintain open chromatin at 
target genes. Within the GC reaction, both TCF3 and TCF4 are responsible for regulating 
the transcription of the IgH constant region genes through the binding of three 3’ 
enhancers: HS3A, HS1/2, and HS3B48. Through regulation of the IgH locus, these 
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transcription factors effectively control the class switch recombination (CSR) dynamic of 
developing B-cells. Upregulation of the IgH heavy and light chain genes also leads to 
increased levels of surface BCR molecules and BCR signaling, and these effects are 
further amplified by their repression of the tyrosine protein phosphatase non-receptor type 
6 (PTPN6), which encodes the negative regulator of BCR signaling SHP148,56. 
TCF3 and TCF4 are also responsible for inducing the expression of the cell cycle 
accelerators Cyclin D3 (CCND3) and E2F transcription factor 2 (E2F2) and for 
downregulating the expression of the tumor-suppressor RB transcriptional corepressor 1 
(RB1)56. Moreover, antagonism of TCF3 and TCF4 prevented AID activation in response 
to anti-CD40 and Interleukin 4 (IL-4) stimulation48. Both transcription factors were found 
to bind to multiple enhancers at the AID locus and elicit upregulation. These results make 
it unsurprising that the absence of E2A and E2-2 led to the dramatic loss of plasma cell 
levels due to a lack of differentiation48,49. 
The inhibitor of DNA-binding/differentiation (ID) proteins, particularly Inhibitor of 
DNA binding 3 (ID3), are the main antagonists of TCF3 and TCF4 function. They repress 
bHLH E-box binding protein function through heterodimerization, thus preventing them 
from binding their targets through sequesteration57. ID proteins are structurally-similar 
enough to bind TCF3 or TCF4 but lack a DNA-binding domain, which prevents 
transcription after heterodimerization is complete58. For instance, the expression of the 
Inhibitor of DNA binding 2 (ID2) regulator resulted in the loss of AID, a key TCF3/TCF4 
target59. The ID3 gene serves as a negative regulator of plasma cell differentiation, and 
its downregulation is essential for TCF3 and TCF4 expression, which allows them to 
promote their targets49. These data were particularly important in determining that TCF4 
could serve a redundant role in the case of TCF3 knockout, effectively replacing its 
function. This study also identified genes required for GC development and organization 
under the regulation of TCF3 and TCF4, including BTB domain and CNC homolog 2 
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(BACH2), POU2AF1, and CXCR4. Interestingly, BCL6 expression was lost in the absence 
of TCF3 and TCF4, but it did not appear to be directly activated through TCF3 binding. 
The likely scenario is the E-protein-mediated upregulation of MEF2B, a key BCL6 
activator. These key studies have identified TCF3 and its related partner TCF4 as key 
regulators of AID, CSR, and plasma cell differentiation. 
 
1.4 Perils of Normal B-cell Differentiation 
Lymphocyte differentiation is an intrinsically volatile process. Unique cellular 
machinery designed to induce mutations that improve antibody binding and rapid clonal 
expansion in response to BCR antigen engagement or cross-linking designate B-cell 
development as a tumultuous process with numerous opportunities for deregulation and 
lymphomagenesis. Nearly 60 subtypes of lymphomas and leukemias are due to oncogenic 
events that disrupt the delicate molecular balances at specific developmental stages60. 
Each subtype aligns to the stage of development from which it originated. This designation 
is referred to as Cell of Origin (COO). COO designation has progressed from 
morphological assessment by pathologists to molecular characterizations defined by gene 
expression profiles (GEP), but several diseases remain difficult to distinguish. Exploiting 
the relationship between a lymphoma and its normal B-cell counterpart likely holds the key 
to improving therapy. With an estimated 72,580 patients diagnosed with Non-Hodgkin’s 
Lymphoma (NHL) in 2016 followed by 11,520 deaths, new understandings of this disease 
are more urgent than ever61. In this section, I aim to introduce common mechanisms of B-
cell developmental deregulation followed by a focus on those that lead to Diffuse Large B-
cell Lymphoma (DLBCL). 
 The first challenge presented by B-cell development is the rearrangement of the 
immunoglobulin genes necessary to form a functional BCR through V(D)J recombination. 
This process relies on double-stranded DNA breaks initiated by the recombination-
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activating genes (RAG1 & RAG2)2. These breaks are resolved by the non-homologous 
end-joining repair apparatus, but occasionally these breaks lead to chromosomal 
aberrations and translocations. A key example is the t(14;18) translocation, which places 
the pro-survival B-cell lymphoma 2 (BCL2) oncogene under the regulation of the IgH gene, 
heavily amplifying its expression. This translocation is observed in approximately 20-30% 
of DLBCL patients62. Further down the developmental process, CSR and SHM are utilized 
to improve the IgH isoform and antigen binding of the antibody variable regions, 
respectively. Both processes generate DNA breaks and predispose to translocations, such 
as the t(8;14) translocation that places the MYC oncogene under the heavy expression of 
the IgH gene in 10-15% of DLBCL cases6263. CSR is implicated in translocations involving 
the IgH gene given its normal role adjusting this gene region. AID-mediated SHM 
concurrently affects region of translocation during cooperative CSR, but it is not limited to 
regions of DNA strand breaks. It can target non-immunoglobulin loci, such as the BCL6 
oncogene64. Approximately 30% of DLBCL cases carry a translocated BCL6 gene 
juxtaposed with IgH on chromosome 1462. Aberrant by-products of RAG V(D)J 
recombinase and AID highlight the turbulent process of B-cell development and the ample 
opportunities for lymphomagenesis65. 
 
1.5 BCR Signaling and Components 
B-cells serve as an agent of the immune system, characteristically through 
targeted elimination of pathogen through antibody binding, but antibodies are only 
secreted by plasma cells, the final product of B-cell development. Antibodies exist as 
transmembrane receptor proteins on the outer surface of developing B-cells as BCR 
molecules during development. A functional BCR is composed of a heavy chain and a 
light chain combination connected through disulfide bonds. The acquisition of a functional 
BCR distinguishes immature B-cells from form pre-B-cell precursors. BCR antigen 
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engagement or cross-linking triggers a protein signaling cascade that culminates with the 
activation of pro-survival and proliferative gene programs (Figure 3)6. Developing B-cells 
that fail to develop a proper BCR or are self-reactive are subject to negative selection 
through a lack of stimulatory survival signals66. Immature B-cells that transition from the 
BM complete their maturation in the periphery. B-cells that do not encounter cognate 
antigen recirculate through the blood and follicular regions of the lymphoid tissues and 
rely on basal levels of BCR signaling for their survival. The activation and clonal expansion 
of these B-cells entering the GC requires antigen-induced BCR signaling in addition to 
signals from cytokine receptors and co-stimulatory receptors. This stimulation is mediated 
by CD4+ T helper cells, namely the TFH cells5. B-cells with the greatest affinity for 
presented antigen will receive the most proliferation and pro-survival signals, thus 
positively selecting them based on BCR antigen recognition capabilities. BCR affinity 
maturation is driven by the expression of AID. This enzyme is responsible for 
immunoglobulin CSR and SHM of the BCR variable gene regions responsible for binding 
antigen67. BCR-binding affinity is the ultimate measure of B-cell binding ability after antigen 
presentation, and as a result, it controls the activation of a powerful growth and survival 
program. 
 
1.5.1 Proximal BCR Kinase Activity 
Downstream BCR signaling is initiated through cognate antigen binding or ligand-
independent BCR auto aggregation. This facilitates the transphosphorylation of the ITAM 
residues on the cytoplasmic tails of the immunoglobulin-associated heterodimer CD79A-
CD79B proteins by Sarcoma tyrosine protein (SRC) kinases5. LYN proto-oncogene (LYN) 
is the primary SRC kinase responsible for phosphorylation the ITAM regions, which results 
in the recruitment of spleen tyrosine kinase (SYK) and to a lesser extent the Zeta chain 
associated protein (ZAP70) kinase. Interestingly, LYN acts as a negative regulator of SYK 
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and the low-affinity Fragment crystallizable region (Fc) receptor for IgG isotype B-cell co-
receptor molecule (FcyRIIB) by phosphorylation of regulatory tyrosine residues68. 
However, higher levels of SYK and LYN protein expression or activity have been reported 
to increase lymphoma cell survival69,70. SYK recruitment culminates with the activation of 
the downstream B-cell Linker Protein (BLNK). BLNK recruits phospholipase C gamma 2 
(PLCG2) and Bruton’s tyrosine kinase (BTK) to facilitate the mobilization of calcium 
ions8,71. Additionally, PLCG2 binds to activated GTPase RAS (RAS) to promote the 
activation of extracellular signal-regulated kinase (ERK), a hallmark regulator of B-cell 
proliferation72.  
 
PLCG2 phosphorylation of BTK ultimately leads to the activation of nuclear factor 
NF-kB. NF-kB activity subsequently propagates BTK through proteasomal and 
transcriptional control73. The NF-kB transcription factor family is composed of two main 
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subunits p50 (known as NFKB1) and p65 (known as RELA) that form a heterodimer. They 
are responsible for promoting differentiation, cytokine signaling, and proliferation, and 
protection against apoptosis. NF-kB activation is initiated by the degradation of the 
inhibitor of NF-kB (IkBa). This is accomplished through the activation of the INB kinase 
(IKK) complex, which consists ofD E and J subunits. IKKE phosphorylates IkE at Ser32 and 
Ser36 and designates it for ubiquitination and proteasomal degradation. Assembly of the 
IKK complex begins with protein kinase CE (PKCE) activation via PLCG2-generated 
diacylglycerol (DAG) and increased calcium signaling due to Phosphatidylinositol-4-5-
biphosphate 3 kinase (PI3K) activity. PKCE coordinates the multimerization of the 
CARD11-BCL10-MALT1 signalosome (CBM) complex. The CBM is comprised of the 
Caspase recruitment domain family member 11 (CARD11), Mucosa associated lymphoid 
tissue lymphoma gene 1 (MALT1), and B-cell lymphoma 10 (BCL10)74. This complex 
associates with IKKD subunit, IKKE subunit, and NF-kappa-b essential modulator (IKBKG 
or NEMO) to dissociate IkBa from NF-kB. Under normal circumstances, IkBa sequesters 
NF-kB outside of the nucleus by masking nuclear localization signals necessary for its 
translocation. IKKE phosphorylation frees NF-kB from IkBa, allowing the transcription of 
nearly 150 targets, many of which go on to engineer proliferative and pro-survival 
prgrams75. IKKE-mediated activation of NF-kB is normally opposed by Tumor necrosis 
factor alpha induced protein 3 (TNFAIP3), a deubiquitinase and negative regulator of 
canonical NF-kB signaling76. TNFAIP3 inactivates IKKE by removing regulatory K63-linked 
polyubiquitin chains from IKKJ, disassociating the complex. 
SHP1 is likely the primary phosphatase responsible for counteracting SYK and 
LYN activity and serves as a key negative regulator of BCR signaling. Surprisingly, LYN 
plays roles a dual role as a repressor of BCR signaling by serving a primary SHP1 
recruiter. LYN phosphorylates immunoreceptor tyrosine-based inhibitory motifs (ITIM) on 
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the intracellular FcJRIIb or CD2277. SHP1 dephosphorylates CD79A and CD79B and 
quenches BCR signaling. SHP1 inactivation results in increased calcium signaling and 
autoimmunity, but it does not lead to B-cell transformation78. Nonetheless, it is poorly 
expressed in many hematological malignancies, often the result of aberrant promoter 
methylation and silencing79. 
 
1.5.2 PI3K/AKT Activity 
The PI3K gene family is a collection of heterodimeric enzymes involved in cellular 
growth, proliferation, differentiation, intracellular traffic, and survival. Hence, they carry a 
subsequent role in BCR signaling and cancer development. Class I PI3K molecules are 
composed of a regulatory (p85) and catalytic (p110) subunit. There are 4 catalytic Class I 
isoform genes (PIK3CA, PIK3CB, PIK3CG, and PIK3CD) and 6 regulatory Class I isoform 
genes (PIK3R1, PIK3R2, PIK3R3, PIK3R4, PIK3R5, PIK3R6), the most common being 
PIK3R1 (p85D). The p110D (PIK3CA) and p110E (PIK3CB) isoforms are expressed in all 
cells, but the p110G (PIK3CD) isoform is primarily expressed in leukocytes and is essential 
for survival80. It is suspected that it evolved alongside the immune system81.  
PI3K enzymes play a vital role in B-cells through BCR signaling pathway 
modulation. To begin, activated SYK and LYN kinases phosphorylate intracellular CD19 
or the Phosphoinositide-3-kinase adaptor protein 1 (PIK3AP1) YXXM tyrosine residues, 
which attracts the regulatory PI3K p85 subunit82,83. Catalytic isoforms, namely PIK3CD, 
are recruited to the bound p85 subunit and form a full PI3K complex. Once assembled 
near the cell surface, the PI3K complex generates the lipid second messenger 
phosphatidylinositol-(3,4,5)-trisphosphate (PIP3) by phosphorylating phosphatidylinositol-
(4,5)-bisphosphate (PIP2)84. They are the only enzymes capable of this conversion. 
PIK3CD has been implicated to be involved with c-MYC upregulation along with an inferior 
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patient prognosis in DLBCL when expressed at high levels85. This work also identified high 
PIK3CD expression as a prognostic indicator via immunohistochemistry and PIK3CD-KO 
inhibits downstream AKT signaling, rendering cell cycle arrest at the G1 phase. Although 
PIK3CD is the primary isoform found in B-cell PI3K complexes, the PIK3CA isoform has 
recently been shown to associate with B-cell PI3K complexes and play an important role 
sustaining BCR signaling following the induced loss of BCR expression86. Both PIK3CD 
and PIK3CA are capable of playing an oncogenic role when overexpressed, but PIK3CD 
is the only isoform capable of sustaining constitutive activity, due to its unique lipid-binding 
domain87. 
Conversion of PIP2 to PIP3 is opposed by Phosphatase and Tensin Homolog 
(PTEN) and SH2 Domain-Containing Inositol 5-Phosphatase 1 (SHIP1) through the 
dephosphorylation of PIP3 to PIP288. Under normal circumstances, phosphorylated 
Ribosomal protein S6 (S6) protein, which is downstream of PI3K/AKT signaling, activates 
nuclear PTEN for cytoplasmic release, thus serving as a mechanism of feedback 
inhibition89. PTEN is often lost in malignancies, leading to aberrant signaling, but the rate 
of PTEN loss is notably lower than average in hematological malignancies. This could be 
due to amplification of Mir-17-92, which encodes a PTEN-targeting microRNA90,91. 
Epigenetic silencing, mutation, genomic loss are additional means of PTEN expression 
loss. Functional redundancy between PTEN and SHIP1 could explain why PTEN loss isn’t 
selected for as strongly92. 
The PI3K-mediated production of PIP3 advances downstream BCR signaling 
through the inducible recruitment of PI3K dependent protein kinase I (PDK1), BTK, and 
AKT serine-threonine kinase (AKT)5. PI3K-mediated recruitment of BTK to the plasma 
membrane is essential for its function and provides a link between PI3K signaling and 
calcium signaling through BTK-dependent activation of PLCG281. Following the activation 
of the PI3K pathway, AKT is recruited to the plasma membrane where it is activated 
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through phosphorylation of Thr308 by PDK1 and Ser473 by the mechanistic target of 
rapamycin (mTOR) complex93. AKT activation leads to the promotion of downstream pro-
survival and proliferation gene targets. For instance, AKT is known to phosphorylate and 
thereby inhibit two key regulators of cell cycle progression and survival in B-cells: glycogen 
synthase kinase 3 (GSK3) and BCL2 agonist of cell death (BAD).5 GSK3 targets include 
the cell cycle regulators CCND3, MYC, and the anti apoptotic protein myeloid cell 
leukemia sequence 1 (MCL1). GSK3 phosphorylation of these targets normally promotes 
their ubiquitination and degradation94. MYC-dependent B-cell lymphomagenesis due to 
CD19 expression has been associated with increased AKT activity and inhibition of 
GSK395. AKT also phosphorylates the BH3-only protein BAD on Ser136, providing a 
docking site for the 14-3-3 adaptor, which induces the release of BAD from its targets 
(such as BCL2) and cytosolic sequestration96. Perhaps most importantly, AKT 
phosphorylation is responsible for the inhibition and cytosolic retention of the Forkhead 
box class O (FOXO) transcription factor family. FOXO1, FOXO3a, and FOXO4 are all 
expressed in B-cells and each contain conserved Ser/Thr residues that can be 
phosphorylated by AKT97. Phosphorylation induces 14-3-3 mediated re-localization of 
FOXO proteins from the nucleus to the cytoplasm, where they are subject to proteasomal 
degradation. Thus, AKT blocks the transcription of FOXO targets, which have been shown 
to negatively regulate the cell cycle and promote apoptosis. For instance, FOXO proteins 
are responsible for promoting the pro-apoptotic BCL2-like 11 (BCL2L11) gene and its 
protein product, BIM, and induce the expression of the cell death Fas ligand (FasL)98. 
 
1.5.3 JAK/STAT Activity 
Janus kinase (JAK) and STAT proteins are emerging components of BCR 
signaling. These pathway components are responsible for transmitting information from 
extracellular chemical signals to the nucleus, resulting in DNA transcription and 
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expression of genes involved in immunity, proliferation, differentiation, and apoptosis99. A 
particular signaling cascade is made of three key components: a cell surface receptor 
partial to a target ligand, a Janus kinase (JAK), and two Signal transducer and activator 
of transcription (STAT) proteins. In B-cells, the binding of cytokines to their respective 
receptors on the B-cell surface activates a JAK-family kinase to phosphorylate tyrosine 
residues on the receptors. This phosphorylation creates a binding site for proteins 
possessing a SH2 binding site. SH2-containing STAT proteins, such as Signal transducers 
and activators of transcription 1/3/5 (STAT1/STAT3/STAT5), are recruited to the receptor, 
where they are also phosphorylated by JAKs. Phosphorylation triggers STAT 
heterodimerization with other STAT proteins or homodimerization. Activated STAT pairs 
migrate to the nucleus to activate a large set of genes100. Phosphorylation signals are 
eventually removed by protein tyrosine phosphatases and suppressors of cytokine 
signaling (SOCS). Under normal physiological circumstances, cytokine signals can lead 
to the stimulation of important B-cell activation pathways necessary for pathogen response 
and survival. This migration is presumably facilitated through interaction between STAT3 
and the NF-kB dimers101. Mutations in the Myeloid differentiation primary response 88 
(MYD88) gene (L265P) upregulate gene signatures associated with NF-kB, JAK-STAT3, 
and type I interferon signaling activation102. MYD88 activation induces the secretion of IL-
6 and IL-10, which subsequently feeds the activation of JAK-family kinases when 
stimulating cytokine receptors. This leads to an aggressive signaling phenotype often 
observed in ABC-like DLBCL cases. Mutant MYD88 signaling can also causes Interferon 
beta 1 (IFNE) production, secretion, and the subsequent activation of type I interferon 
target genes. IFNE-mediated inhibition of immune cells could contribute to the poor 
survival observed in these patients103. Moreover, IFNE enhances the expression of Toll-
like receptor 7 (TLR7) and Toll-like Receptor 9 (TLR9), leading to a feed-forward MYD88 
21 
 
signaling axis104. Interestingly, some B-cell lymphomas with wild-type MYD88 still display 
increased STAT3 mobilization, indicating that some tumors may utilized TLRs to engage 
MYD88 and STAT3. This pathway is prominent within several important human tissues, 
making it notoriously difficult to target without eliciting side effects. 
 
1.6 Diffuse Large B-cell Lymphoma Epidemiology and Cell of Origin Classification 
Lymphoma is the 7th most prevalent cancer in the United States and is comprised 
of distinct subgroups (Table 1)61. Lymphoid neoplasm frequencies can be divided as 
follows: 6% of cases are traditional Hodgkin’s Lymphoma cases, 6% of cases are T-cell 
or NK-cell lymphomas, and 88% are comprised of B-cell lymphomas (Figure 4)105. The 
most frequent Non-Hodgkin’s B-cell Lymphoma subtype is Diffuse Large B-cell Lymphoma 
(DLBCL). This subtype accounts for 28% – 32% of all lymphoma diagnoses105. In spite of 
recent advances in monoclonal antibody therapy leading to the Rituximab, 
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) combination, up 
to 40% of patients eventually experience refractory or relapsed disease and ultimately 
death. Functional genomics studies have allowed cases of DLBCL to be subdivided into 
two biologically and clinically relevant disease subtypes: germinal center B-cell (GCB)-like 
type or activated B-cell (ABC)-like type, based on their transcriptional similarity to the 
respective populations of primary B cells106. Diseases are found to occur in similar ratios, 
with GCB-like DLBCLs accounting for 17% of total lymphoma diagnoses and ABC-like 
accounting for 15%107. GCB-like patients carry a median age of 61, an approximately 60% 
5-year survival rate, and boast cure rates above 50%. ABC-like DLBCL cases are 
characterized by a more aggressive disease reflective of an activated B-cell and an inferior 
prognosis. The median age of diagnosis is 66, 5-year survival rates are approximately 
40%, and the cure rate is only around 30%105. Rates of ABC-like survival are inferior to 
those of GCB-like patients (Figure 5). The inability to treat so many DLBCL patients and 
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1.6.1 Germinal Center-like (GCB) DLBCL 
GCB-like DLBCL cells resemble those found in the germinal center. GCB-like gene 
expression profiles closely resemble those of normal GC B-cells, often deriving from light 
zone B-cells. Furthermore, these cells have highly mutated immunoglobulin genes with 
ongoing SHM in malignant clones, and most GCB-like cells have also undergone CSR 
based on gene expression profiles108. The following traits serve as the current means to 
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define GC cells as the cell of origin for GCB-like DLBCL cases and that they are trapped 
at this stage of differentiation.  
While the pathogenesis of the GCB-like subtype remains poorly understood, a few 
biologically relevant lesions have been identified, but none appear frequently enough to 
serve as defining characteristics. These include the amplification of REL at chromosome 
2p15 (26% of cases) and loss of PTEN at chromosome 10q25 (12%)90. Chromosomal 
translocations involving MYC and BCL2 can be detected in approximately 10% and 40% 
of cases, respectively. Cases of “double-hit” GCB-like DLBCL that incur both of these 
translocations are associated with a particularly poor prognosis109. 
Epigenetic deregulation has emerged as an important characteristic in GCB-like 
DLBCL cases thanks to recent work. Aberrant activity of the Enhancer of zeste 2 polycomb 
repressive complex 2 subunit (EZH2) histone methyltransferase, a component of the 
polycomb repression complex-2 (PRC2), can be observed in approximately 21% of GCB-
like cases due to heterozygous mutations at Y641N110. This mutation results in a gain-of-
function phenotype with epigenetic modifications that serve to prevent further 
differentiation and is not observed in ABC-like cases111,112. Mutant EZH2 proteins prefer 
modifying mono or di-methylated H3K27 to tri-methylated H3K27, while WT EZH2 protein 
preferentially performs the zero-to mono-methylation reaction. The activity of mutant EZH2 
thus depends on the epigenetic landscape left behind by the WT enzyme. Mice 
engineered to express the EZH2 mutant develop GC hyperplasia, indicating that these 
mutations lead to lymphoma113. Moreover, GCB-like lymphoma can be induced in mice 
with the characteristic BCL2 translocation after expression of the mutant EZH2, validating 
the cooperative role that these lesions play113,114. EZH2 is also responsible for the silencing 
of key post-GC differentiation pathway genes, such as Cyclin dependent kinase inhibitor 




 A key feature of many GCB-like DLBCL cases is the overexpression of the BCL6 
transcription factor. Causes of increased BCL6 include translocations that set it under IgH 
promotion, SHM of regulatory regions leading to constitutive activity, and gains targeting 
the 3q27 locus115. BCL6 serves as a transcriptional repressor of GC B-cell differentiation 
and is found at the highest levels in the germinal center. Perturbations leading to increased 
expression can stall differentiation in the GC and lead to tumor formation. First, BCL6 
represses the PRDM1 gene, responsible for coding the master regulator of plasmacytic 
differentiation BLIMP1, along with its inducer IRF4116,117. Secondly, BCL6 represses the 
cell cycle inhibitors CDKN1A (also known as p21) and Cyclin dependent kinase inhibitor 
1B (CDKN1B) (also known as p27kip1), allowing the cell cycle to run unchecked in GC B-
cells118. The final function of BCL6 is the repression of important regulators of the DNA 
damage response, which normally allows cells to persist through the DNA damage 
inflicted by SHM and CSR. Examples include TP53, ATR serine/threonine kinase (ATR), 
and Checkpoint kinase 1 (CHEK1)119,120. Interestingly, BCL6 aids the positive selection of 
GCB-like clones capable of resisting apoptosis by repressing the BCL2 pro-survival 
oncogene and NFKB1 (p50) subunit116,121. Recent observations have identified that 
sustained BCL6 expression may not be necessary to set off oncogenesis and that a “hit-
and-run” mechanism occurring earlier in B-cell development may be a more appropriate 
model122. 
Recent work has defined the PI3K/PTEN signaling axis as a dynamic GCB-like 
DLBCL signaling relationship. The loss of PTEN through mutation, silencing, and DNA 
copy number loss allows unfettered PI3K signaling to downstream targets such as AKT. 
PTEN is a major regulator of the PIP2 to PIP3 conversion that PI3K coordinates, and its 
loss represents an important prognostic marker. Recent studies identified that PTEN was 
only detectable in 31 out of 77 GCB-like patient samples (44%), in contrast to the 124 out 
of 143 detections in non-GCB-like samples (87%)123. These results indicated that although 
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PTEN loss is not 100% specific to the GCB-like subtype, it is highly associated. 
Reintroduction of WT PTEN to PTEN-deficient cell lines would lead to cell death and stark 
reductions of phosphorylated AKT123. Moreover, the reintroduction of PTEN saw the down-
regulation of MYC associated gene targets, as well as MYC itself123. These results 
highlighted the key role of PI3K signaling and its importance surrounding 
lymphomagenesis.  
Another key element of the PI3K pathway in GCB-like lymphomas is the ratio 
between the p100 catalytic isoforms PIK3CD and PIK3CA. PIK3CD is a leukocyte-specific 
isoform and PIK3CA is ubiquitous across tissues, but they are both found in varying ratios 
in GCB-like and ABC-like DLBCL124. Many therapies avoid targeting PIK3CA due to 
substantial off-target effects and the resulting adverse patient symptoms. Recent work has 
highlighted that higher PIK3CA/PIK3CD (D/G) ratios are associated with poor prognosis 
and inhibitor response124,125. The results went on to call for dual D/G inhibitors, despite the 
weight loss experienced in mice124,125. One of the more interesting caveats of emerging 
work on this pathway is an increasing association between the PI3K signaling axis and 
aggressive BCR signaling and the ABC-like subtype. Although normally characterized as 
a GCB-like mechanism, the ability of ABC-like DLBCLs to reject PIK3CD-based therapies 
through BTK-mediated upregulation of the PIK3CA isoform represents an important 
observation. PI3K modulation of the CARD11-containing CBM complex that is responsible 
for shuttling NF-kB heterodimers into the nucleus for transcription highlights an emerging 
connection between PI3K signaling and the ABC-like program125. Another recent 
publication reported down-regulation of NF-kB-mediated signaling and transcriptional 
programs after AKT inhibition, adding another key insight towards a defined PI3K/BCR 
signaling relationship124. Lastly, the work demonstrates the vast potential for synergy 
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through BTK and PI3K inhibition, as previously validated through high-throughput 
screens125,126. 
 
1.6.2 Activated B-cell-like (ABC) DLBCL 
ABC-like DLBCL has been defined as a distinct subgroup from GCB-like DLBCL 
because the gene expression profiles of these lymphomas resemble mitogenically 
activated peripheral B-cells, not GC B-cells. Reliance on the sustained stimulation of NF-
kB transcriptional program through activating mutations in the CARD11 oncogene, 
constitutively-activating MYD88 mutations stimulating the TLR pathway, and increased 
levels of BCR signaling have been credited for its ability to refract therapy at a higher rate 
than GCB-like DLBCL102,103,127.  
CARD11 pairs with BCL10 and MALT1 proteins to form the CBM complex, which 
is required for the activation of IKKE and the classical NF-kB pathway. Under normal 
circumstances, the CARD11 protein is kept in an inactive conformation through an 
intramolecular interaction between its linker and coiled-coil domain. PKCE 
phosphorylation of the CARD11 linker domain is thought to relieve this association, 
allowing CARD11 to translocate to the plasma membrane. There, it binds BCL10 and 
MALT1 to form the CBM complex and activates IKKE. In both GCB-like and ABC-like 
DLBCL (but primarily ABC-like), activating mutations target the CARD11 coiled-coil 
domain127. While WT CARD11 is distributed throughout the cytoplasm in an inactive form, 
mutant CARD11 isoforms form discrete cytoplasmic clusters that segregate with BCL10 
and MALT1 without regulation, independently initiating NF-kB signaling127. Mutations in 
the coiled-coil domain inhibit linker domain binding, potentially relieving the necessity of 
PKCE phosphorylation. ABC-like DLBCL cases also incur frequent losses of the TNFAIP3 
tumor suppressor, which opposes the CBM complex, allowing rampant NF-kB 
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activation105. Patients with TNFAIP3 loss face an inferior prognosis than those with a 
functional copy76. The importance of NF-kB repression by TNFAIP3 has been documented 
through rescue experiments that saw the abolishment of NF-kB targets after WT TNFAIP3 
was introduced to cells that previously incurred loss128. The Spi-B transcription factor 
(SPIB) represents another key modulator of the ABC-like program. 25% of ABC-like 
DLBCL cases have either incurred SPIB DNA copy number amplification at the 19q13 
locus or activating SPIB mutations110. SPIB modulates aggressive NF-kB signaling by 
forming a complex with IRF4 that contributes to PRDM1 inactivation as well as CARD11 
modulation, blocking differentiation and facilitating CBM complex formation, 
respectively90,129. These lesions serve as evidence towards the assertion that ABC-like 
DLBCL relies on both of these pathways for survival. 
Constitutive MYD88 signaling due to the L265P mutation triggers the NF-kB 
signaling pathway and is found in approximately 30% of ABC-like DLBCL cases but rarely 
in GCB-like cases. MYD88 is an adaptor protein that couples Toll-interleukin receptor 
(TIR)-containing surface molecules, such as TLRs, to various downstream signaling 
pathways, including NF-kB, p38 MAP kinases, and type I interferon secretion130. The 
involvement of innate immune signaling pathways is a unique feature of ABC-like DLBCL. 
MYD88 carries out its function by coordinating the Interleukin-1 receptor-associated 
kinases (IRAK) family into a helical signaling complex through interactions between the 
MYD88 and IRAK death domains131. Activating L265P mutations occur at a highly 
conserved residue in the Toll/Interleukin-I domain hydrophobic core. This isoform is 
capable of nucleating the formation of a complex involving IRAK4 and phosphorylated 
IRAK1102. Cell lines harboring L265P MYD88 mutations die upon knockdown and can be 
rescued by mutant MYD88 but not WT MYD88, demonstrating a key oncogenic role. 
Unregulated mutant MYD88 signaling also induces the secretion of IL-6 and IL-10. When 
these cytokines bind to their respective receptors, JAK-family kinases phosphorylate and 
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activate STAT3 signaling100. STAT3 enters the nucleus and promotes the transcription of 
a large number of genes. Moreover, STAT3 potentiates NF-kB signaling, likely through a 
physical interaction between the p50 and p65 dimer subunits101. 
DLBCL tumors rely on the surface BCR to engage downstream pathways that 
grant proliferative and survival advantages. ABC-like DLBCL cases heavily express the 
IgM isotype, indicating their escape from the GC reaction and resulting CSR103,132. This is 
a key characteristic of ABC-like disease functionality, as IgM isoforms deliver more 
mitogenic signals that resist differentiation than their IgG counterparts, which promote 
ERK and MAPK signals that lead to differentiation133. The presence of the surface BCR is 
essential to DLBCL survival in most cases, as is the presence of functional CD79A and 
CD79B ITAM regions6,66. These observations led to the BCR-independent definition of 
“tonic” BCR signaling, which relies on the high expression and activity of the PI3K complex 
to engage AKT and coordinate downstream survival pathways capable of sustaining cells 
without a BCR. Interestingly, BCR ablation not only leads to decreased NF-kB and 
MAPK/ERK activity, but PI3K targets as well, evidenced by reduced AKT 
phosphorylation103. In contrast, BCR-dependent cells that have undergone BCR ablation 
cannot be rescued by NF-kB signaling86. 
Morphologically, ABC-like DLBCLs are characterized by clustered BCR molecules 
on their surface, while GCB-like BCR molecules are diffusely spread across the cell 
surface103,134. Crosslinking between clustered BCRs could provide an explanation towards 
their increased proximal signaling levels. Constitutive BCR signaling can be inspired by 
activating mutations in the CD79A or CD79B adaptor genes, leading to a dependence on 
NF-kB signaling. These mutations were found in 21.1% of ABC-like DLBCL cases and 
only 3% of GCB-like cases103. They reportedly contribute to increased levels of surface 
BCR and subsequent signaling through the prevention of BCR internalization upon 
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stimulation, which is normally the case through negative regulatory functions of LYN 
kinase135.  
Downstream BCR signaling begins when phosphorylated CD79 ITAM regions 
attract SYK kinase, which goes on to ignite the protein kinase cascade. Although SYK 
inhibitors have fared poorly in the clinic, they have provided vital insight towards BCR 
pathway functionality. SYK inhibitors are lethal for both GCB-like and ABC-like DLBCL cell 
lines, indicating BCR signaling reliance in some form within both subtypes70. SYK or its 
target LYN are responsible for phosphorylating and activating the tyrosine kinase BTK 
after it is recruited to the cell membrane via its Pleckstrin homology (PH) domain, which 
recognizes the PIP3 generated through PI3K activity136. BTK serves as a central 
component of BCR signaling and is responsible for activating IKKE and the NF-kB 
pathway7. Activated BTK forms a complex with BLNK, which goes on to phosphorylate 
PLCG2. Activated PLCG2 kinase converts PIP2 into DAG and IP3. IP3 initiates calcium 
release via IP3 receptors on the endoplasmic reticulum. Together, DAG and increased 
levels of calcium signaling activate PKCE, which phosphorylates CARD11 and leads to 
NF-kB activation105. This essential role modulating BCR signaling led to the discovery that 
BTK is necessary for ABC-like DLBCL survival in cases lacking a CARD11 or MYD88 
mutation103. Abrogation of BTK leads to the knockdown of key downstream effectors 
responsible for modulating NF-kB signaling and cellular proliferation and survival 
pathways. BTK therefore represents a defining component of ABC-like DLBCL. 
 
1.7 Clinical Overview of DLBCL 
The most recent World Health Organization (WHO) consensus defines DLBCL as 
a neoplasm of large B-cells arranged in a diffuse pattern60. These definitions are primarily 
based on morphological characteristics, such as the large size of the cells as compared 
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to benign histiocytes in the same tissue section. Notable changes from the 2008 WHO 
definition included COO classification, CD5 expression as a prognostic factor, emphasis 
on double MYC/BCL2 expressors as an adverse prognostic factor, and an intermediate 
classification between Burkitt’s Lymphoma and DLBCL, which includes definitions for 
triple-hit BCL6/MYC/BCL2 translocations as well, specified as High-grade DLBCL. The 
standard therapeutic regimen is the R-CHOP combination, and following treatments are 
based on the initial outcome (Figure 6). Each cycle of R-CHOP takes 21 days, and the 
common side effects include weight loss, indigestion, nausea, vomiting, fatigue, difficulty 
sleeping, and anemia. The Rituximab antibody targets the CD20 B-cell surface marker, 
targeting them for immune destruction. Cyclophosphamide targets the DNA of cancer cells 
and signals them to stop dividing. Doxorubicin is an anthracycline that blocks 
Topoisomerase II beta (TOP2B), a key enzyme that cancer cells need for growth. 
Vincristine is an alkaloid that interferes with gene replication. Prednisolone is a 
corticosteroid that eases inflammation and overreactions of the immune system. Together, 
these molecules form a potent anti-cancer combination.  
DLBCL typically presents in elderly patients, with a median age in the 70’s107. 
However, it does occur in young adults and rarely in children. DLBCL is more common in 
males, presenting a 4:3 ratio61. Most patients present an aggressively-growing tumor mass 
involving multiple lymph nodes and extranodal sites137. The most common site of primary 
DLBCL is the gastrointestinal tract, but virtually any tissue may serve this purpose. B-cell-
specific symptoms are present in approximately one-third of patients and include fever, 
weight loss, and night sweats. Symptoms can be related to the affected area as well. For 
example, gastrointestinal lymphomas can cause stomach pain and nausea. 
Approximately 50% of patients present stage I or II disease, with the remaining 50% 
presenting stage III or IV disease137. DLBCL can be further subdivided based on BM 
involvement. Concordant disease aligns with DLBCL involvement in the BM, while 
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disconcordant disease is defined by low-grade B-cell lymphoma BM involvement138. 
Concordant disease is regarded as a poor prognostic indicator. 
 
1.7.1 Morphology 
DLBCL cells are morphologically similar for the most part, sharing large cell size 
and a diffuse pattern that totally or partially effaces normal nodal or extranodal 
architecture139. Variable numbers of infiltrating small T-cells and histiocytes are present in 
all cases. Several cytological variants of DLBCL have been characterized. These include 
the Centroblastic, Immunoblastic, and Anaplastic variants. The most common 
morphological variant is Centroblastic DLBCL, which accounts for approximately 80% of 
cases139. These cases are primarily composed of rapidly proliferating centroblasts that a 
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re-characterized by a moderate amount of cytoplasm, round to oval vesicular nuclei, and 
vesicular chromatin. This variant can be further classified based on the composition of 
centroblasts. Monomorphic tumors with over 90% centroblasts are classified separately 
from polymorphic tumors that consist of less than 90% of centroblasts that include a 
mixture of centrocytes and immunoblasts. The Immunoblastic morphological variant itself 
represents 8-10% of DLBCL cases and can be defined by the presence of at least 90% 
immunoblasts or less than 10% centroblasts in the neoplasm137. Immunoblastic cells can 
display marked plasmacytic differentiation and often need to be distinguished from 
plasmablastic lymphoma and multiple myeloma. The cells are characterized by moderate 
to abundant basophilic cytoplasm, a prominent trapezoid nucleolus, fine chromatin 
attached to the nuclear membrane, and large cell size140. Lastly, the Anaplastic variant, 
which represents only 3% of cases, is characterized by very large lymphoma cells and 




Given the myriad of closely related lymphoma subtypes, immunophenotypic 
evaluation by immunohistochemistry or flow cytometry is required to establish a DLBCL 
diagnosis. Neoplastic DLBCL cells express pan B-cell surface antigens CD19, CD20, and 
CD22, and approximately 50-70% of cases express surface or cytoplasmic 
Immunoglobulin, most often IgM followed by IgG and IgA139. DLBCL immunophenotype 
plays an important role in diagnosis, but it also allows clinicians to identify potential targets 
for therapy. For instance, high expression of the CD20 surface receptor signals for the use 
of R-CHOP. CD19 is often the target of emerging CAR-T cell therapies for the treatment 
of hematological malignancies, and about 20-25% of DLBCL cases are positive for PD-L1 
expression and correlative amplification of the 9p24.1 locus, a positive therapeutic 
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indicator for PD1 inhibitors141,142. The predictive capabilities of DLBCL 
immunophenotyping have proven to be a powerful diagnostic and therapeutic tool. 
 
1.7.3 Tumor Microenvironment 
Lenz and colleagues determined that survival after treatment of DLBCL is 
influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor 
microenvironment143. This work was spurred by the analytical definition of four key 
prognostic DLBCL signatures that reflected distinct biological attributes associated with 
survival among patients who received CHOP chemotherapy144. These included the 
following signatures: Germinal Center B-cell, Proliferation, MHC class II, and Lymph Node. 
The Germinal Center B-cell signature serves as a counterpart to the Activated B-cell 
signature that was derived in the same analysis. The Germinal Center B-cell signature 
was associated with better rates of overall survival that mirrored the GCB-like molecular 
classification and the lower rates of survival observed in molecularly classified ABC-like 
tumors. The Proliferation signature was associated with a poor prognosis, MYC 
expression and its target genes, the Heat shock protein 22 (HSP22) and Nucleoplasmin 
3 (NPM3) genes, and the ABC-like DLBCL subtype. The MHC class II signature was 
similar between GCB-like and ABC-like subgroups. This signature was also associated 
with a positive outcome, indicating that higher expression and thus higher antigen 
presentation to the immune system played an immunoregulatory role145. Lastly, the Lymph 
Node signature was associated with a positive outcome and was composed of genes 
encoding components of the extracellular matrix and Connective tissue growth factor 
(CTGF), a mediator of fibrosis that promotes the synthesis of the matrix146. The genes 
included in this signature are associated with increased sclerotic reactions, and they are 
characteristically expressed in macrophages and NK-cells, again suggesting that 
antitumor immune responses are positive prognostic factors. The surrounding tumor 
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microenvironment thus carries a heavy influence over disease prognosis and can be 
determined with these tools in order to best diagnose and treat patients. 
Building on these signatures, Lenz and colleagues created three contemporary 
gene expression signatures – termed Germinal-Center B-cell, Stromal-1, and Stromal-2 
that were capable of predicting survival in both CHOP and R-CHOP patients143. The 
prognostically favorable Stromal-1 signature reflected extracellular matrix deposition and 
histiocytic infiltration, while the unfavorable Stromal-2 signature reflected tumor blood 
vessel density. Genes included in the Stromal-1 score encode components of the 
extracellular matrix modifiers of collagen synthesis, matrix remodelers, genes associated 
with the monocytic lineage, and CTGF 143. Stromal-1 tumor microenvironments are 
associated with a monocyte-rich host reaction to the lymphoma and abundant extracellular 
matrix deposition. In contrast, the Stromal-2 signature genes encode endothelial cell 
markers and key regulators of angiogenesis143. These gene signatures have proven to be 
key diagnostic and prognostic factors capable of directing treatment of DLBCL tumors.  
 
1.7.4 DLBCL Tumor Evolution 
DLBCL tumors are characterized by notable heterogeneity. The advent of high- 
throughput sequencing has provided novel insights into the DLBCL genome and its ability 
to adapt when confronted with therapy147. Sequence analysis has revealed stark 
differences between patient tumor genomics at diagnosis. These results have led to a shift 
towards sequencing DLBCL tumors that have progressed in order to gain a greater 
understanding of “relapse genomics”. Insights from these tumors have revealed evidence 
of branched tumor evolution in which tumors consisting of multiple clones that share a 
common ancestor but differ in alterations that occur later in evolutionary progression. The 
wealth of genetic diversity within the tumor provide an ideal substrate upon which 
branched evolution may occur and produce extensive inter and intra-tumor heterogeneity. 
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Targeting DLBCL tumors thus represents a significant challenge when considering the 
myriad of adaptive resistance mechanisms that a given tumor may harbor. 
New work has sought to define the molecular underpinnings of refractory or 
relapsed DLBCL. This work furthers the notion that these patients can be treated as their 
own vulnerable population. Several key methods have emerged to uncover the drivers of 
refractory or relapsed disease. These include comparing primary specimens of patients 
who fail therapy vs. those that achieved long-term remission, profiling refractory or 
relapsed biopsies to characterize potential driver alterations, and comparing separate 
patient cohorts to measure characteristics enriched in refractory or relapsed individuals. 
An important caveat to these studies is the limited by the quality of some samples, which 
may be too poor to properly reflect tumor heterogeneity. 
These studies were able to identify several factors capable of predicting disease. 
First, two studies observed that mutations in Tumor protein P53 (TP53), a common event 
in DLBCL, were associated with poor survival and were enriched in refractory or relapsed 
patients as opposed to those that responded to treatment148,149. These results indicated 
that TP53 loss may play a key role resisting the standard treatment regimen of R-CHOP, 
and despite minor prevalence in the initial tumor population, TP53 mutation was fully-
acquired at relapse148. Another common loss enriched in refractory or relapsed DLBCL 
patients is that of the Beta-2-microglobulin (B2M) and CD58 genes. B2M is a key 
component of the MHC class I molecule, and CD58 is a cell adhesion molecule 
responsible for T-cell and Natural Killer (NK)-cell activation. The combined loss of these 
molecules is strongly associated with impaired anti-tumor immune response in these 
patients150. One study observed that 5 or 7 refractory DLBCL patients incurred losses in 
one or both of these genes151. Deletions of the Cyclin dependent kinase inhibitor 2A 
(CDNK2A) and Cyclin dependent kinase inhibitor 2B (CDNK2B) genes are also enriched 
in the primary samples of patients who have failed to respond to primary therapy, 
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particularly in the ABC-like DLBCL subgroup152. Activating Signal transducer and activator 
of transcription 6 (STAT6) D419 mutation has been specifically observed in relapsed GCB-
like DLBCL patients, indicating that the activation of the JAK/STAT pathway may be 
associated with advanced disease153. These findings were supported by the observation 
that mutations in the JAK/STAT negative regulator Suppressor of cytokine signaling 1 
(SOCS1) were reported exclusively in non-relapsed DLBCL patients and a favorable 
outcome154. Lastly, the loss of the inhibitors of NF-kB signaling, NFKB inhibitor epsilon 
(NFKBIE) and NFKB inhibitor zeta (NFKBIZ), were implicated in the activation of the NF-
kB pathway in cases of refractor or relapsed DLBCL153. 
Genetically similar collections of lymphoma cells have been observed to evolve 
under Darwinian rules of selection as therapy progresses and the low degree of genetic 
similarity between the primary tumor and the resulting refractory or relapsed tumor 
indicates rapid selection for traits that can resist therapy. Importantly, the founding clone 
of resistance is often present in the primary tumor, even if it comprises less than 1% of the 
total cells. Such spatial heterogeneity also makes it difficult to assess the presence of 
predictive resistance clones from the primary tumor. However, the advent of technologies 
such as circulating tumor DNA (ctDNA) analysis have provided researchers with a deeper 
understanding of this disease timeline. Most results indicate that resistant tumors undergo 
convergent evolution towards the activation of a specific pathway. In the case of DLBCL, 
this is often the BCR signaling pathway. For instance, C481S mutations in BTK that confer 
resistance to Ibrutinib were observed to arise from two genetically distinct clones that both 
gained a selective advantage from the mutation, despite making different changes in the 
DNA that led to C481S155,156. New technologies such as ctDNA and Digital Droplet 
Polymerase Chain Reaction (ddPCR) have allowed researchers to map changes to 
genetic composition of tumors in real time, as well as V(D)J profiling capable of predicting 
refractory or relapsed DLBCL157–159. Understanding the evolutionary patterns of DLBCL 
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are key towards developing therapies that are capable of cornering selected pathway 
components and eliminating the opportunity for resistance. 
 
1.7.5 Diagnosis, Staging, and Treatment Response 
DLBCL is a highly heterogeneous disease, and proper diagnosis, prognosis, and 
staging techniques are vital towards applying a proper therapy. A full patient work-up is 
required for potential DLBCL patients and includes morphological assessment, 
immunophenotypic analysis, cytogenetic analysis (conventional and Fluorescent in situ 
hybridization [FISH]), and molecular diagnostic assays that assess gene mutations and 
copy number alterations. COO classification can be performed using 
immunohistochemical algorithms or by GEP performed on fixed tissue using recently 
developed small gene panels. Alterations in MYC, BCL2, and BCL6 can be identified 
through immunohistochemistry, conventional karyotyping, breakapart probes, or FISH in 
cases with little fresh tissue. For diagnostic purposes, a 40% immunohistochemistry cut-
off is the current standard for MYC aberrations60. Mutations in the genes MYD88, CXCR4, 
EZH2, CD79A, CD79B, CARD11, and TP53 have powerful prognostic significance for 
planning personalized therapeutics. DLBCL also requires adequate tissue to be obtained 
to support immunohistochemical and molecular testing, usually through a fine needle 
aspiration biopsy. 
Proper staging methods allow clinicians to identify patients that may benefit from 
an aggressive therapy while sparing inaccurate diagnoses that could potentially lead to 
overly toxic therapies. The International Prognostic Index (IPI) was developed in 1994 to 
stratify risk in DLBCL patients160. Five variable comprise the IPI: age (cut-off >60 years), 
Eastern oncology group (ECOG) performance status (0-1 vs. 2-4), serum Lactic acid 
dehydrogenase (LDH) level (cut-off above normal range), number of extranodal sites (0-
1 vs. 2 or more), and stage (I-II vs. III-IV). IPI stratifies patients into four risks groups: low 
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(0-1), low-intermediate (2), High-intermediate (3), and high (4-5). The advent of Rituximab 
and the success it has had treating older patients has called for an age-adjusted IPI 
revision, and new suggestions are currently being debated161. 
Ann Arbor criteria primarily assess the spread of DLBCL between lymph node 
region as a measure of disease staging (Table 2)162. Areas of involvement include the left 
and right cervical regions, left and right auxiliary regions, left and right infraclavicular 
regions, left and right pelvic regions, left and right inguinal femoral regions, supraclavicular 
region, occipital region, mediastinal region, hilar region, periaortic region, and mesentery 
region163. Additional staging modifiers have been added to account for Non-Hodgkin’s 
disease biology, such as the absence of specific B-cell symptoms (A and B) and the 
involvement of a single proximal extranodal site (E). 
ECOG criteria for performance status is another factor incorporated into the IPI. 
This score reflects the effect of the tumor on the patient, with a greater ECOG score 
indicating a greater need for palliative treatment due to the symptomatic manifestation of 
the disease. The score is primary based on the patient’s ability to perform normal motor 
activities. These include patients that are fully active and capable of performing all pre-
disease tasks (0), patients restricted to light or sedentary activity (1), patients that a re 
mobile and confined to a bed or chair less than 50% of the time with the capacity for self 
care (2), Patients confined to a bed or chair over 50% of the time and limited capacity for 
self care (3), patients that are totally confined to bed or chair with ability for self care (4), 




Measuring patient response to chemotherapy is vital for assessing initial 
successful treatment and directing further treatment. Rapidly evolving technology has 
allowed clinicians to incorporate [18F] fluorodeoxyglucose (FDG) position emission 
tomography (PET), flow cytometry analysis, and immunohistochemistry instead of relying 
on nodal size and examination165. PET allows clinicians to measure tumor respiration and 
stage, re-stage, or assess therapeutic response. Accurate assessments stemming from 
this technique can direct continued treatment, new therapies, or a can signal a 
confirmation of remission. Patients are classified into one of four categories based on their 
response: complete response (CR) is there is a complete disappearance of the disease, 
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partial response (PR) if the disease has not appeared at new sites and regression has 
occurred at the original site, progressive disease (PD) if a lesion that was present prior to 
therapy has grown by over 50% in size or if there is a new lesion, or stable disease (SD) 
if no changes to the tumor have been observed. Post treatment assessments are 
bolstered by additional criteria, such as the size of the liver, spleen, lymph nodes, and the 
presence of lymphocytic infiltrate in the bone marrow (concordant or disconcordant). 
 
1.8 Second-line DLBCL Treatment Overview 
Despite significant progress since initially treating DLBCL with volatile 
combinations of chemotherapy, this heterogeneous disease demands new targeted 
therapies with the potential to cure refractory or relapsed disease and ease patient burden. 
The advent of the CHOP chemotherapy combination in 1993 and the addition of the anti-
CD20 antibody Rituximab led to DLBCL cure rates as high as 50% (Figure 7)166. The R-
CHOP combination has since become the standard of care for all DLBCL patients in the 
immunotherapy era, and the most recent 5-year survival rate hovers around 62.5%167. The 
other recommended first-line therapy is Rituximab in combination with Etoposide, 
Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH). However, 
depending on the IPI, 20-50% of patients treated with either standard regimen may be 
expected to refract or relapse from therapy or relapse after achieving a complete 
response168. Of this subset, only 30-40% are expected to respond to salvage 
chemotherapy and subsequently undergo autologous stem cell transplantation (ASCT)169. 
Regardless of transplant success, 50% of patients will ultimately relapse170. A recent study 
comprehensively examined refractory and relapsed DLBCL patients undergoing second 
line therapies after failing R-CHOP and uncovered a dismal median overall survival 
between 5-10 months, owing to the aggressive nature of this disease subset171. The study 
did not discriminate based on COO subtype classification and designated all DLBCL 
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patients that refract or relapse from standard therapy as a single population. The results 
highlighted a glaring need for second line therapies capable of successfully treating this 
population. The following therapies serve as a final line of defense for patients who failed 




1.8.1 Proximal BCR Kinase Inhibition 
The BCR signaling pathway has long since been identified as a driving force 
among patients who refract or relapse from conventional therapy. One of the most 
promising agents is the small molecule Ibrutinib (formerly PCI-32765), an irreversible 
small molecule inhibitor that covalently binds to the C481 residue on BTK, a central BCR 
signaling component172–174. NF-kB signaling was severely impacted, and cells reliant on 
this pathway were eliminated. This inhibitor is especially well-endowed by its specificity 
and resulting pharmacodynamics172. Ibrutinib has even been recently approved as a 
treatment option for patients suffering from Host vs. Graft disease, the first small molecule 
inhibitor to do so175. Reported mechanisms of resistance include the selection of cells with 
mutant C481S resides, independent signaling through mutant CARD11 or MYD88, or 
reliance on the PI3K/AKT pathway103,176. 
Seeking to follow the success of Ibrutinib, therapies targeting the BCR proximal 
BCR signaling kinases were actively developed. Fostamatinib was developed as an 
inhibitor of the upstream SYK kinase in an effort to cut off the pathway entirely177. Thus 
far, this inhibitor has not found the same success treating DLBCL patients that Ibrutinib 
did (22% ORR), but it has been more successful treating patients with Chronic 
Lymphocytic Leukemia (CLL), boasting a 55% ORR178. Some of its effectiveness is 
predicted to be due to off-target effects70,179. 
 
1.8.2 PI3K/AKT Inhibition 
The PI3K pathway has recently emerged as an actionable therapeutic pathway in 
both GCB-like and ABC-like DLBCL subtypes and several new targeted therapies have 
been produced as a result94,180. The lymphoid-restricted PIK3CD catalytic isoform makes 
this pathway especially attractive since other tissues would be spared PI3K inhibition. The 
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PIK3CD inhibitor Idelalisib (formerly CAL-101) was the first therapy to find success in 
CLL/Small lymphocytic lymphoma (SLL) phase I/II trials, but initial trials failed to achieve 
a DLBCL response181. Recent reports have predicted that this could be due to PIK3CA 
upregulation in response to PIK3CD inhibition and proposed the use of the dual 
PIK3CA/PIK3CD inhibitor Copanlisib125. In spite of the in vitro success in ABC-like DLBCL 
models, the historically poor off-target effects of dual PIK3CA/PIK3CD inhibitors were 
highlighted by this study through in vivo experiments, as mice treated with Copanlisib 
suffered a 20% reduction in body weight over several weeks while counterparts treated 
with Idelalisib only lost 5% of their body weight125. The dual inhibitor AZD8835 was also 
observed to be efficacious in ABC-like cell line models and was capable of down-
regulating NF-kB target gene expression profiles124. Again, mouse models suffered higher 
weight loss under AZD8835 treatment, but the results nonetheless spotlight the vital 
importance of PIK3CA to the aggressive BCR signaling profile of ABC-like DLBCL. 
Tapping into the potential of PIK3CA inhibition in ABC-like DLBCL therefore remains 
unachievable until frequent patient side effects stemming from PIK3CA inhibition across 
various bodily tissues. 
Despite a safer profile than dual PIK3CA/PIK3CD inhibitors, Idelalisib suffered 
from a lack of effectiveness and a less-than stellar safety profile of its own. The next-
generation PIK3CD inhibitor Umbralisib was developed with the hopes of greater 
effectiveness and less off-target effects, and initial results revealed superior results in both 
cases182,183. The main structural change between the molecules reflected this, as the 
Idelalisib backbone known to interact with hepatic enzymes was removed while 
maintaining PIK3CD binding potential. In a defining study, Umbralisib was found to 
unexpectedly inhibit casein kinase-1 epsilon (CK1H) alongside PIK3CD184. CK1H is 
responsible for phosphorylating and activating eukaryotic translation initiation factor 4E 
(elF4E)- binding protein (4E-BP1), which oversees translation of the MYC oncogene. This 
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finding represents a paradigm shift in PI3K inhibition, because although it has been 
observed that this pathway played a role in MYC regulation, no therapy has been observed 
silencing its translation, especially not one with an outstanding safety profile. Umbralisib 
effectiveness is thus likely augmented through the inhibition of MYC, a particularly 
valuable trait for treating DLBCL harboring MYC translocations. 
Inhibiting the downstream target of PI3K, AKT, has emerged as another strategy 
for treating this pathway. The AKT inhibitor AZD5363 has been found efficacious in GCB-
like cell line models, even those with PTEN deficiency, highlighting divergent ranges of 
specificity based on DLBCL subtype124. This treatment was also found to downregulate 
MYC, but no direct relationship has been identified as it was for Umbralisib. Exploiting this 
treatment in patients with PTEN deficiency thus represents an opportunity for novel 
therapy in a patient population with poor prognostics. 
 
1.8.3 Bromodomain Inhibition 
Acetylation of lysine residues on histones is a primary mechanism of establishing 
epigenetic memory, and context-specific recognition of acetyl-lysine is primarily mediated 
by bromodomains185. Recent research has established a compelling rationale for targeting 
the bromodomain and extra terminal domain (BET) family member Bromodomain 
containing 4 (BRD4) based on its propensity for promoting the transcription of genes 
primarily involved in the M/G1 transition and facilitating mitotic progression. BRD4 has 
since emerged as an attractive therapeutic target in cases of aggressive DLBCL. A 
prototypical triazolo-diazepine inhibitor capable of disrupting the acetyl-lysine binding site 
of BRD4 has emerged: JQ1186. This inhibitor binds to the acetylated lysine site on BET 
domains and displaces BRD4 from nuclear chromatin in cells187. When treated with JQ1, 
DLBCL cells suffer from growth arrest but do not display consistent patterns of apoptosis. 
These effects were specific to DLBCL and Burkitt’s Lymphoma in this study, as the 
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Hodgkin Lymphoma line L428 did not respond186. BRD4 inhibition was also found to to 
downregulate oncogenic transcriptional pathways related to the MYD88/TL10, MYC, and 
BCL6 oncogenes, often overloading key enhancer elements in the genome186. In some 
cases MYC itself was observed to lose protein expression188,189. Xenograft mouse models 
injected with the Toledo DLBCL cell line were successfully treated with JQ1, indicating 
that the epigenetic modulations of the GC program were enough to deregulate tumors. 
While these results provided compelling rationale for further clinical investigation, JQ1 has 
not been able to consistently treat patients with success, likely owing to its poor in vivo 
half-life. 
The potential for BRD4 inhibition remains in spite of poor clinical JQ1 efficacy. 
Recent studies uncovered that BRD4 and the E-box transcription factor TCF4 were co-
dependent in the rare and aggressive plasmacytoid dendritic cell neoplasm 
(BPDCN)190,191. This work identified TCF4 as a master regulator of the BPDCN program 
and that BRD4 is directly responsible for TCF4 expression. In a critical finding, BRD4 
inhibition with JQ1 led to the elimination of TCF4 and its transcriptional targets. Targeting 
transcription factors is a difficult task, and this research identified an exciting new 
approach for this disease. The loss of MYC expression post-JQ1 treatment was to be 
expected, but the TCF4 targets BCL2 and TLR9 were also significantly reduced191. The 
loss of these targets subsequently decreased BPDCN viability. TCF4 
immunohistochemistry identified it as a facilitating factor for BPDCN diagnosis, and the 
TCF4 transcriptional program was found to be oncogenic. JQ1 BRD4 inhibition 
accomplished the elimination of TCF4 and its targets and provided the initial basis for 
targeting oncogenic transcription factors in BRD4-dependent lymphoid malignancies. 
Although new small molecule therapies have been produced since JQ1, targeting 
BRD4 for elimination with proteolysis-targeting chimera (PROTAC) constructs has 
emerged as the most exciting prospective therapy. PROTACs recruit BET proteins to the 
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E3 ubiquitin ligase for degradation, including BRD4192. Unlike small molecule inhibitors 
that lead to protein accumulation, BRD4 protein is abolished by PROTAC therapy192,193. 
The exciting potential of these constructs is currently being tested in vitro throughout a 
number of lymphoid malignancies dependent on BRD4. 
 
1.8.4 Immunotherapy 
Harnessing the therapeutic potential of the immune system has been a primary 
focus of hematological malignancy research for the past decade, and DLBCL treatment is 
no exception. Lenalidomide is a derivative of thalidomide approved in 2016 for the 
treatment of refractory or relapsed non-Hodgkin’s Lymphoma. Lenalidomide modulates 
NK antibody-dependent cell-mediated cytotoxicity, immune synapse formation, and 
increases their overall number and activity. T-cell synapse formation is also modulated, 
along with stimulation of CD4+ activity, CD8+ activity, and dendritic cell presentation. 
Lastly, it downregulates pro-inflammatory and pro-angiogenesis cytokines194. 
Lenalidomide has shown mixed clinical results treating refractory or relapsed DLBCL since 
its introduction, with two trials achieving overall response rates (ORR) of 19% and 28% 
with complete response rates (CRR) of 7% and 12%195,196. Recent work has clarified that 
it is most effective when treating non-GCB-like DLBCL cases, likely due to MYD88 
deregulation through IKAROS family zinc finger 1 (IKZF1) and IKAROS family zinc finger 
3 (IKZF3) targeting and subsequent IRF4/SPIB complex downmodulation129,197. Non-GC-
like DLBCL patients achieved a 52.9% ORR vs. 8.7% for GCB-like patients, and CRR 
rates were similar with 23.5% vs. 4.3%197. Single agent Lenalidomide may not be the 
future of DLBCL treatment, but the Immunomodulatory mechanisms have uncovered 
viable avenues for tumor exploitation. 
The introduction of chimeric antigen receptor (CAR) T-cells as a DLBCL treatment 
represents a dramatic shift towards immunotherapy treatments. Genetically modified 
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autologous T-cells expressing the CD19 receptor are considered one of the greatest steps 
forward for DLBCL therapy since the introduction of Rituximab. The excitement is 
warranted, as trials across the country are reporting the successful, sustained treatment 
of refractory and relapsed DLBCL patient populations. The phase II ZUMA-1 multicenter 
trial provided pivotal insights towards this new therapy. KTE-C19 CAR-T cells were 
successfully manufactured in 99% of patients, and receipt of the therapy was achieved in 
an average of 17.4 days142. 51 patients achieved an ORR of 76% (47% CR and 29% PR), 
a significant improvement from the expected 20%142,171. Polymerase chain reaction (PCR) 
revealed exponential expansion upon CAR-T infusion and sustained proliferation198. In 
spite of the success, 20% of patients incurred grade 3 or 4 cytokine release syndrome or 
neurological events142. An unknown array of adverse effects, limiting patient eligibility 
criteria, and manufacturing turnaround timetables represent the greatest challenges for 
implementing this therapy, save for the enormous financial burden it places on patients 
and their families. The success of CAR-T treatments in DLBCL will continue to grow, but 
many patients will nonetheless need to rely on other avenues. 
 
1.8.5 BCL2 Inhibition 
The pro-survival BCL2 gene is a hallmark of aggressive DLBCL. 40% of patient 
tumors stain for strong levels of BCL2 expression, serving as a significant prognostic factor 
for IPI scores199. Increased expression can results from activating mutations, 
translocation, or DNA copy number gain and lead to therapy rejection and poor 
prognosis200. The inhibitor Venetoclax (ABT-199) has seen moderate success, but like 
many previous BCL2 inhibitors, it fail to spare the BCL-XL gene, which is ubiquitously 
expressed in platelets and leads to adverse side effects when treated200,201. Pro-apoptotic 
members of the BCL2 family such as BCL2-associated X apoptosis regulator (BAX), 
BCL2-homologou antagonist killer (BAK), and BIM bear one or more BCL2-homology (BH) 
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domains, providing challenges for a targeted therapy. Combining Venetoclax, or another 
BCL2 inhibitor, with other DLBCL therapeutics remains an exciting possibility since most 
agents do not kill cancer cells directly but cause stresses to be detected by the cell, 
resulting in apoptosis. Safe inhibition of BCL2 thus represents an opportunity for the 
improvement of a wide array of therapies. 
 
1.8.6 NF-kB Inhibition 
Targeting transcription factors is a challenge for scientists, and the oncogenic NF-
kB heterodimers are no exception. Therapeutic approaches were initiated by Bortezomib, 
a proteasomal inhibitor that prevented the degradation of the NF-kB inhibitor IkBa, leading 
to the scheduled degradation of NF-kB heterodimers. Therapy was most effective in 
patients with the ABC-like DLBCL subtype as opposed to the GCB-like subtype202. The 
major pitfalls of NF-kB therapies is that long-term inhibition could be associated with major 
toxicities, including the loss of innate immune function203. Moreover, IKKE inhibition could 
result in the compensatory activation of IKKD and resume signaling, thus resisting 
therapy204. Although this route of therapy has the potential to effectively treat aggressive 
lymphomas, most targeted therapies have focused on inhibiting upstream signaling 
stemming from BCR signaling. 
 
1.9 Mantle Cell Lymphoma 
Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin’s 
lymphoma, comprising about 6% of total cases107. It is only present in approximately 
15,000 patients at this time. 5-year survival rates are up to 70% for limited-stage patients 
and 50% for advanced patients. Mantle cell lymphoma can be identified as a CD5+ 
antigen-naïve pregerminal center cell within the mantle zone that surrounds normal GC 
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follicles205. MCL cells generally over-express Cyclin D1 (CCND1) due to a chromosomal 
translation t(11;14) placing it under the control of the IgH promoter. MCL is a systemic 
disease with involvement if the gastrointestinal tract and the bone marrow. 
There are currently no standards of treatment for MCL, and there is no consensus among 
clinicians on how to treat it optimally. Possible avenues have included R-CHOP, total body 
irradiation, HSCT (autologous or allogeneic), and several emerging immunotherapies. 
Clinical trials are ongoing. Recent insights have identified the BCR pathway signaling as 
a source of aggressive MCL growth206,207. Subsequently, the small molecule BTK inhibitor 
Ibrutinib has been approved for treatment of MCL patients by the FDA174. Other BCR 
inhibitors have sought to target proteasomal degradation of IkE (Bortezomib) as well as 
inhibition of mTOR and PI3K. Aggressive BCR signaling is a trait that MCL shares with 
DLBCL, and more parallels arise as its role in both diseases becomes further elucidated. 
 
1.10 Dissertation Significance and Aims 
DLBCL diagnoses are among the most prevalent in the country, comprising over 
20% of NHL diagnoses61. Despite these urgent statistics and the advent of CHOP 
chemotherapy regimens and the addition of the CD20-targeted Rituximab antibody, 5-year 
survival rates have hovered near 50% for nearly a decade167. Patients that experience 
relapse or refractory disease face a particularly dismal outlook, with a median survival rate 
of 6.3 months171. The fail to cure or treat a large portion of DLBCL patients demands the 
research of novel, personalized avenues of therapy capable of acting against the drivers 
of relapsed or refractory disease. In order to achieve these goals, we must gain a greater 
understanding of the BCR signaling pathway as well as the genomic drivers of disease 
that could possibly serve as predictors of disease or even therapeutic targets. 
The primary aims of this study were to elucidate BCR signaling pathway 
mechanisms capable of predicting a therapeutic response, identify novel drivers of 
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aggressive disease, and designate a personalized treatment response. These aims were 
accomplished through comprehensive in vitro models and screens, as well as the analysis 
of available molecular profiles and techniques. Combining these approaches and their 
related methods revealed novel insights and partnerships within the BCR signaling 


















Chapter 2: Materials and Methods 
2.1 Cell Culture Technique 
Non-Hodgkin’s Lymphoma cell lines were utilized in this thesis to measure levels 
of sensitivity in the presence of targeted small molecule therapies, assess intracellular 
levels of BCR signaling, and confirm the role of molecular targets in vitro. Data were used 
to confirm or dispute previous and emerging observations. Tumor-derived cell line models 
have been used for a number of investigative purposes, including oncogene and tumor 
suppressor gene discovery, characterization of cell signaling, assessment of drug efficacy. 
Cell lines are relatively inexpensive and effective models of oncogenic disease, but cancer 
is a complex condition that varies widely between individual patients. The inherent 
heterogeneity of a given disease is not 100% replicated though the use of cell lines, and 
the lack of a tumor microenvironment leads to alterations in environmental reactions and 
behaviors. Although not fully representative of the in vivo state, a wide range of cell line 
models grants higher confidence in observations. Oncogenic pathways remain intact in 
cell line models, and as a result, they provide an excellent means for assessing pathogenic 
mechanisms, signaling, and inhibitor response. Of the 38 cell lines used in this study, 34 
had complete Next Generations Sequencing (NGS) data available. Sequencing was 
completed by Green lab members. 
A total of 38 cell line models were used in this investigation (Table 3). Cell lines 
were obtained from the DSMZ cell line bank and confirmed by Short tandem repeat (STR) 
typing at Genetica DNA laboratories (NC, USA). All cell lines were maintained in the 
recommended RPMI medium (Life Technologies) supplemented with 10% fetal calf serum 
(FCS) (Corning) and penicillin/streptomycin (Sigma-Aldrich). FCS was heat-inactivated at 
65 °C for 30 minutes after defrosting. Media solutions were filtered for contaminants before 
use with cells (Sigma-Aldrich). Cells were grown in a 5% CO2 environment at 37 qC. Cell 
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lines are routinely tested for mycoplasma infection using MycoHunter PCR detection kit 
(GenHunter). Cell line populations were regularly counted and set to 250,000 cells/mL 
concentrations for optimal growth. Populations that had undergone a large number of 




Ibrutinib is an orally bioavailable selective and irreversible small-molecule BTK 
inhibitor used to treat various B-cell malignancies that rely on BCR signaling. Celera 
Genomics developed Ibrutinib as a covalent binding molecule used for studying BTK 
function. It was originally termed PCI-32765 and is currently marketed as Imbruvica. 
Ibrutinib inhibits BTK function through binding the ATP-binding pocket at C481172. Ibrutinib 
also reduces CLL chemotaxis towards C-X-C motif chemokine ligand 12 (CXCL12) and 
C-X-C motif chemokine ligand 13 (CXCL13), down-modulates CD20 expression, and has 
recently been approved for the treatment of Graft vs. Host disease in patients who have 
not responded to standard therapy173,175,208. Recurrent lymphoma patients treated with 
Ibrutinib can expect > 90% occupancy of the BTK active site in peripheral blood 
mononuclear cells up to 24 hours after doses of > 2.5 mg/kg/day and carries a biological 
half life of 4-6 hours174. Ibrutinib is generally well-tolerated in patients, with a majority of 




Umbralisib is an orally bioavailable PIK3CD inhibitor with a characteristically safe 
patient symptom profile182. Greater safety profiles owe to high specificity to the PIK3CD 
catalytic subunit, limiting off target effects stemming from PIK3CA and PIK3CB binding, 
as well as a lack of a heterocyclic backbone, which had previously been implicated to react 
with hepatic enzymes in previous PIK3CD inhibitors such as Idelalisib. A prolonged half-






2.4 In Vitro Evaluation of Ibrutinib and Umbralisib  
Cell line populations were counted and re-suspended at 200,000 cells/mL. Cells 
were seeded into a 3 X 10 section of a 96-well plate. Cells were set at 10,000 cells/well in 
50 PL. Concentrations of Ibrutinib and Umbralisib were prepared from 10 mM stocks 
(SelleckChem, TG Therapeutics). 40 PM stocks were assembled, and 8 Log(2) serial 
dilutions were made. Inhibitor concentrations of 40 PM, 20 PM, 10 PM, 5 PM, 2.5 PM, 1.25 
PM, 0.625 PM, 0.313 PM, and 0.156 PM were prepared. Including a Dimethyl sulfoxide 
(DMSO) control, each concentration was set in a column with the 50 PL of cells, diluting 
the concentrations by 50% to their intended levels (Figure 8). Media was set in the wells 
surrounding the assay to protect cells from contamination. Cells were incubated for 96 
hours at 37 °C. Cell viability was analyzed with Alamar Blue Cell Viability reagent after 
incubation (Thermo Scientific)209. 10 PL of Alamar Blue reagent was added to each well 
and incubated at 37 °C for 75 minutes. Cells were then screened for fluorescence on a 
Cytation 6 plate reader. Results were normalized for blank wells with only Alamar blue 
reagent and media. Triplicate cell well samples were averaged, and relative survival was 
calculated based on DMSO control treatment results. Median effective dose (ED50) 
determination was performed on Graphpad Prism software with sigmoidal inhibition 





2.5 Cell Line Fixation/Permeabilization, Barcoding, and Intracellular Phosphoflow 
1 million cells were counted and pelleted at 300 G for 5 minutes and washed once 
with PBS with 2% FCS once under the same conditions. Cells were then re-suspended in 
a PBS solution containing 12% formaldehyde for fixation and allowed to incubate for 15 
minutes. Cells were centrifuged at 300 G for 5 minutes and washed once with PBS with 
2% FCS once under the same conditions. Cells were then re-suspended in 1 mL of ice-
cold Methanol and incubated on ice for 10 minutes. 
During fixation and permeabilization, the following four concentration levels of 
Pacific Orange and Dylite 405 (Pacific Blue) dyes were assembled before barcoding. 
Stock A (for 1 Pg/mL): 200 PL volume = 40 PL of 1 mg/mL dye stock + 160 PL DMSO. 
Stock B (for 0.25 Pg/mL): 200 PL volume = 50 PL of Stock A + 150 PL DMSO. Stock C (for 
0.05 Pg/mL): 200 PL volume = 40 PL of Stock B + 160 PL DMSO. Stock D (for 0.0 Pg/mL): 
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200 PL DMSO. These concentration solutions were used to create a 4 X 4 grid on a 24-
well plate. 30 PL of each stock were added in a crosswise fashion for a final volume of 60 
PL in each well. Additional wells were included for compensation controls. 1 mL containing 
1 million cells in methanol were added to each well, followed by an additional 1 mL of PBS. 
Cells were allowed to incubate in the dark at 4 °C for 30 minutes. Following incubation, 
cells were added to a conical tube containing 4 mL of PBS with 2% FCS and centrifuged 
at 300 G for 5 minutes. Cells were washed once more with 5 mL of PBS with 2% FCS and 
pelleted again. Cells were resuspended in 100 PL of PBS. 10 PL portions of each cell 
population were combined in three tubes. The first tube was left unstained, the second 
tube was stained with Intracellular (IC) Panel I antibodies, and the third tube was stained 
with IC Panel II antibodies (Figure 9). A separate fourth tube was analyzed for surface 
BCR isotype with the surface panel staining antibodies. After antibody staining incubation 
at 4 °C for 30 minutes, cells were washed once more and results were acquired on the 
LSR-II Green. Of the 16 resulting populations, the four corner populations of the barcoding 
plot were kept as the same cell line to ensure that barcoding did not affect IC antibody 
staining results. Each population was gated and analyzed individually according to 
standard protocols (Figure 10). These methods allowed each sample to be exposed to 











2.6 Synergy Evaluation Assays and Analysis 
Cells were counted and set at a concentration of 200,000 cells/mL. 50 PL of cells 
(10,000 total) were placed in a 6 X 6 grid of wells in a 96-well plate. Duplicate rows were 
treated with Ibrutinib only, Umbralisib only, or a combination. Varying dosages were 
applied to columns of the grid, based on the cell line ED50 value for Ibrutinib or Umbralisib. 
With X representing the cell line ED50 dosage, columns were treated with DMSO control, 
0.125X, 0.25X, 0.5X, 1X, or 2X levels of inhibitor as 50 PL aliquots prepared from inhibitor 
stock solutions (Figure 11). Media was set in the wells surrounding the assay to prevent 
contamination, and cells were incubated for 96 hours at 37 °C. Cell viability was analyzed 
with Alamar Blue reagent following incubation (Thermo Scientific). 10 PL of Alamar Blue 
reagent was added to each well and incubated at 37 °C for 75 minutes. Cells were then 
screened for fluorescence on a Cytation 6 plate reader. Results were normalized for blank 
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wells with only Alamar blue reagent and media. Duplicate samples were averaged, and 
relative survival was calculated based on DMSO treatment column results. Cell inhibition 
and synergy results were calculated using Compusyn software210. Independent 
experiments were performed at least twice to confirm results. 
  
2.6.1 Chou-Talalay Synergy Quantification Method 
Measuring the effectiveness of drug combinations holds immense value for 
disease treatment, from cancer to HIV. Quantifying the effectiveness of drug combinations 
is not only important for identifying synergistic pairs but also for uncovering antagonistic 
relationships that would bode poorly for patients. Faulty claims of synergy are pervasive 
and lead to diminished patient results, not to mention lost opportunity of trying a beneficial 
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therapy. Dr. Ting-Chao Chou and Dr. Paul Talalay jointly produced the “combination 
index” (CI) to quantify and depict synergism210. After combining known mathematical 
principles to define the “additive effect” as CI = 1.0, values less than 1.0 could be defined 
as synergistic, and values over 1.0 could be defined as additive. The definition of the 
additive effect produced a border from which to measure synergy or antagonism. The 
applications were applied to Compusyn computer software by Dr. Joseph Chou, who 
developed a platform for dose-effect analysis based on the mass-action law210. Mass 
action law-based theory defines “median” as the unified common link of a single entity, 
essentially serving the universal reference point for quantification. Combination data are 
collected alongside single-drug doses for compassion and quantified together across a 
spectrum of cellular inhibition levels. This platform provides researchers with simple, 
quantifiable justifications of in vitro combination synergy, which consequentially saves the 
time, energy, and funds that comprehensive mouse work would require to establish the 
same biochemical conclusions. 
 
2.7 Cellular Apoptosis Assays 
To ensure that cell inhibition reflected cell death, we analyzed levels of cell line 
apoptosis after treatment. 1 million cells were set to 200,000 cells/mL concentrations in 6-
well plates. Cells were treated with ED25 and ED50 dosages of Ibrutinib only, Umbralisib 
only, or a Combination. Following incubation for 96 hours at 37 °C, 1 million cells were 
counted and centrifuged at 500 G for 5 minutes at room temperature. Cells were then re-
suspended in 1 mL of Phosphate-buffered saline (PBS) and stained with 10 PL of Hoechst 
DNA-staining dye (BD Biosciences)211. After incubating for 30 minutes at 37 °C, cells were 
centrifuged at 500 G for 5 minutes and suspended in 300 PL of PBS. Cell cycle and cellular 
death events (sub G1 events) were analyzed at the University of Nebraska Medical Center 
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(UNMC) flow cytometry core on an LSR-II Green cytometer (BD Biosciences). The 
resulting data were analyzed on Cytobank Community platform software212. Side and 
forward scatter conditions were applied to ensure that dead or dying cells were properly 
assessed for sub G1 event peaks. 
  
2.8 DNA Copy Number Data Acquisition and Processing 
Publicly available data for single nucleotide polymorphism microarrays and array 
comparative genome hybridization platforms with 200,000 markers were downloaded from 
the gene expression omnibus (www.ncbi.nlm.nih.gov/geo/). These included Affymetrix 
250K and SNP 6.0 platforms, and the Agilent 244K platform. The data originated from 36 
studies, including 9 unique B-cell malignancies aligning with different stages of B-cell 
development150,213–245. For Affymetrix microarrays, raw Affymetrix probe results (CEL) files 
were extracted and copy number predicted using the Affymetrix Copy Number Analysis 
for Genechip (CNAG) tool, with reference to data from 100 Caucasian HapMap samples. 
Agilent data was analyzed using BioConductor143. Data for all arrays were represented as 
Log(2) copy number change and segmented using the circular binary segmentation (CBS) 
tool on GenePattern246. Peaks of significant DNA copy number loss and gain were 
identified using the Genomic Identification of Significant Targets in Cancer (GISTIC2.0) 
tool on GenePattern247. The thresholds utilized for DNA copy number gain and loss were 
0.1 copies, over a region encompassing 100 markers. Frequency and magnitude of copy 
number gains and losses were taken into account with the GISTIC algorithm. 
 
2.8.1 GISTIC 2.0 Algorithm 
The GISTIC2.0 algorithm was developed at the Broad Institute as a tool capable 
of high-resolution characterization of genes being targeted by Somatic Copy Number 
Alterations (SCNA) from thousands of patient cancer genomes (Figure 12)247. DNA copy 
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number gains or losses are often broad, chromosome-wide events. SCNAs may 
potentially affect up to thousands of genes when they are likely driven by only one or a 
few. Less frequent focal gains of “driver genes” are the most responsible for driving 
GISTIC2.0 peaks, as these genes are highly selected for and present in both broad and 
focal lesions. Other copy number analysis tools rely on measuring the frequency of SCNA 
events, but SCNAs have been observed to vary in both size and magnitude248. The 
GISTIC2.0 algorithm uniquely takes both frequency and magnitude into account when 
producing significant peaks. This mechanism allows well-defined regions of genomic gain 
or loss to be identified from hundreds of patient samples. This feature is owed to the 
Ziggurat Deconstruction (ZD) algorithm that deconstructs each segmented copy number 
profile into the most likely SCNAs247. The major advantage of ZD is its ability to delineate 
separate arm-level and focal SCNA based on length by assessing magnitude, as arm-
level gains rarely reach higher amplitudes. A consequential disadvantage is that low or 
moderate focal events are not recognized as a result of the high amplitude filter, but length-
based filtering allows for the computational reconstruction of arm-level and focal 
representation of the cancer genome and thus the inclusion of these events for final 
analysis. Events occupying over 98% of the arm length are also filtered out in order to 
emphasize focal events and improve sensitivity. Driver events tend to be shorter in length 
and higher amplitude, thus allowing GISTIC2.0 to identify regions that are most likely to 







 The GISTIC2.0 algorithm relies on five key steps. First, copy number profiles from 
patients are individually defined based on SNP fluorescence levels throughout the 
genome. This segmentation step is uniform for most copy number algorithm platforms. 
Next, background rates of formation are calculated and the most likely SCNAs are 
identified. SCNAs are then scored based on their probability of occurring by chance, which 
I followed by defining independent regions of statistically significant SCNAs. Lastly, likely 
gene targets within the SCNAs are highlighted as possible driver candidates, producing a 
G-score. Higher G-scores a reflected by lower Q-value significance values. Driver genes 
are identified through a novel approach termed RegBounder that defines likely driver 
genes within a within a genomic region within a specified confidence level (J)247. 
RegBounder was ore likely to identify driver genes and produced narrower boundaries 
than the previous leave-1-out” method247. These features allow GISTIC2.0 to provide a 
vastly more detailed and accurate model of subtype-specific SCNA landscapes. 
  
2.9 Integrative Analysis and Hypergeometric Gene Enrichment Analysis 
Raw CEL files for matched Affymetrix U133 Plus 2.0 gene expression microarray 
data were obtained for 249 DLBCL (GSE11318 and GSE34171) from the Gene 
Expression Omnibus90,234. Data were Robust multichip average (RMA) normalized and the 
two DLBCL datasets batch-corrected using ComBat249. Differential gene expression 
analysis was performed between samples with or without a given lesion using a Student's 
T-test and corrected for multiple hypothesis testing by the Benjamini-Hochberg method. 
Results for each lesion were compiled using the comparative marker analysis tool on 
GenePattern. Resulting Open document format (ODF) files were combined for summary. 
Genes with a fold-change ≥ 1.2 in the direction of the copy number alteration and a false-
discovery rate (FDR) <0.25 were considered statistically significant. To define targets of 
SCNA, the differential gene expression analysis was limited to only the genes within the 
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GISTIC2.0-defined peak of each SCNA. To identify the signature associated with 18q21 
DNA copy number gain, differential gene expression analysis was performed on the 
10,000 most variably expressed genes across the dataset as determined by median 
absolute deviation. Significantly altered genes targeted by DNA copy number gains and 
losses were analyzed separately for enriched gene ontology biological process (GO-BP) 
terms using DAVID, with an FDR<0.25 and a fold-change direction corresponding to the 
direction of the copy number alteration being considered significant250. GenePattern 
GENE-E software was used to create heat maps. 
  
2.10 Survival and Cell of Origin Subtype Association 
In order to visualize co-association, each lesion was scored with a binary 
present/absent classification and clustered using Spearman’s rank correlation. Only 
SCNAs that were present in ≥ 10% of DLBCL tumors (13 gains and 22 losses) and tumors 
that possessed ≥ 2 SCNAs (n = 481) were included. DLBCL tumors were classified by cell 
of origin using the Wright algorithm. Association between SCNAs and COO subtype were 
determined using a Fisher exact test. Overall survival data was collated from previous 
studies for 232 DLBCL patients treated with CHOP combination chemotherapy and 197 
DLBCL patients treated with R-CHOP90,234,251. Associations between the presence of a 
SCNA and overall survival were assessed using a log-rank test. 
  
2.11 Public ChIP-Seq Data Analysis 
Previously described chromatin immunoprecipitation (ChIP) sequencing data for 
TCF4 were downloaded from the gene expression omnibus (GSE75650)191. Raw FASTQ 
files were mapped to the human genome (UCSC hg18) using BWA-Mem, and sorted and 
deduplicated using Picard tools from DNA nexus. The physical location of transcription 
start sites (TSS) for genes with significantly increase expression associated with 18q21 
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DNA copy number gains were collated using the UCSC Table Browser252. Raw data were 
visualized using the integrative genomics viewer, and heatmaps were created for 
visualization of TCF4 signal at transcription start sites using EaSeq software253,254. 
 
2.12 In Vitro Evaluation of BRD4 Inhibitors 
The U2932, RI-1 (aka RIVA), TMD8 and HBL1 cell lines were obtained from the 
DSMZ cell line bank and confirmed by STR typing at Genetica DNA laboratories (NC, 
USA). All cell lines were maintained in the recommended RPMI medium supplemented 
with 10% FCS and penicillin/streptomycin. Cell lines are routinely tested for mycoplasma 
infection using MycoHunter PCR detection kit (GenHunter). The JQ1(+), JQ1(-) and I-
BET151 compounds were purchased from Selleck Chemicals and reconstituted in DMSO. 
For drug treatments, cells were seeded at 250,000/mL and exposed the inhibitor for 24 
hours Radioimmunoprecipitation assay (RIPA) buffer (60 nM Tris HCL, 2% SDS, 10% 
glycerol) plus protease inhibitor cocktail. Western blots were interrogated using α-TCF4 
(clone 1G4, Sigma Aldrich), α-BLNK (clone D8R3G, Cell Signaling Technologies), α-c-
MYC (clone D84C12, Cell Signaling Technologies), α-BCL2 (clone D55G8, Cell Signaling 
Technologies), α-PIK3CA (clone C73F8, Cell Signaling Technologies), α-PTEN (clone 
138G6, Cell Signaling Technologies), and α-BTK (clone D3H5, Cell Signaling 
Technologies). α-GAPDH (clone D16H11, Cell Signaling Technologies) was used as a 
loading control. Flow cytometry was performed by staining 1x106 cells with APC-
conjugated α-IgM (clone G20-127, BD Biosciences), data were acquired on an LSR-II flow 
cytometer (BD Biosciences) and analyzed on Cytobank212. Fold reduction in expression 
of IgM was calculated by dividing the median fluorescence intensity (MFI) of control 
treated cells by that of cells treated with the active compound. All experiments were 




2.13 Western Blot Lysate Preparation and Quantification 
To make whole cell lysates, cells were washed in PBS and lysed using RIPA buffer 
(60 nM Tris HCL, 2% SDS, 10% glycerol) plus protease inhibitor cocktail for 1 hour on ice 
with vortexing every 15 minutes. Samples were centrifuged at 14,800 G for 20 minutes at 
4 °C. Supernatant lysate was collected for immediate analysis or stored at -80 °C. Protein 
concentrations were measured using a Bradford assay (Boston Biosciences). Bradford 
reagent was mixed at a 1:1 ratio with Milli-Q water and aliquoted into 1.5 mL Eppendorf 
tubes. 2 PL of protein sample was added to each tube. A standard curve set was made 
under similar conditions from a stock of 1 Pg/uL Bovine Serum Albumin (BSA). The 
standard curve concentrations were set to 1, 2, 3, 4, 6, and 8 Pg/uL. Protein quantification 
was performed on a TECAN Infinite M200 Pro plate reader using the paired TECAN 
software. Lysates were prepared into uniform 24 PL solutions through the addition of RIPA 
buffer, 10X reducing agent and 4X sample buffer (Life Technologies). Gels were run at 
120V for 1.5 hours and then transferred to Polyvinylidene difluoride (PVDF) membranes 
at 20V for 1 hour. Membranes were next blocked with 5% BSA Tris-buffered saline with 
Tween 20 (TBST) solution for 1 hour with gentle rocking. Membranes were washed three 
times with TBST for 5-minute intervals. Primary antibodies were applied in 3% BSA 
solutions at 1:1000 solutions overnight at 4 °C. Membranes were washed three times with 
TBST the following day and 1:4000 secondary antibody solutions were applied in TBST 
for 1 hour at room temperature with gentle rocking. Membranes were washed three times 
in TBST once again and incubated in a 1:1 mixture of Enhanced chemilumescent (ECL) 
reagent A and B for 60 seconds and then read on a chemiluminescent film developer (Cell 





2.14 Flow Cytometry 
Cells were counted and centrifuged at 300 G (500 G when assessing dead or dying 
cells). Cells were resuspended and washed twice with PBS 2% FCS solution. Staining 
protocols varied, but the standard protocol was to resuspend cells in 100 PL of PBS in an 
analysis tube. 5 PL of antibody was added to each sample and allowed to incubate on ice 
and in the dark for 30 minutes. Following staining, 1 mL of PBS 2% FCS was added to the 
sample, briefly vortexed, and centrifuged at 300 G for 5 minutes. Compensation controls 
comprised a negative bead control of 30 PL, a positive control of 15 PL beads and 15 PL 
α-mouse antibody, and 30 PL of negative beads with 5 PL of control target antibody. Cells 
were resuspended in 300 PL of PBS with 2% FCS and taken to the UNMC Flow Cytometry 
Core for analysis. Analyses were performed on the LSR-II Green flow cytometer (BD 
Biosciences) and analyzed with Cytobank Community software. All flow analyses 
employed standard gating on forward and side scatter profiles to ensure that only live, 
singlet cells were analyzed. Each analysis was performed on at least 20,000 gated events. 
The following antibodies were used for flow cytometry: APC-conjugated α-IgM 
(clone G20-127, BD Biosciences), FITC-conjugated α-IgD (clone IA6-2, BD Biosciences), 
PE-Cy7-conjugated α-IgN (clone MOPC-21, BD Biosciences), Alexa Fluor 647-conjugated 
α-IgO (clone JDC-12, BD Biosciences), FITC-conjugated α-pAKT (clone M89-61, BD 
Biosciences), PE-conjugated α-IkBa (clone 25/IkBa/MAD-3, BD Biosciences), PE-Cy7-
conjugated α-pNFkB p65 (clone K10-895.12.50, BD Biosciences), Alexa-Fluor 647-
conjugated α-pS6 (clone N7-548, BD Biosciences), PE-CF594-conjugated α-pSTAT1/3/5 
(clones K51-856, 49/p-Stat3, 47/Stat5 (pY694) BD Biosciences), PE-conjugated α-PTEN, 
and FITC-conjugated α-BCRprox (pBTK, pSYK, pLYN, pBLNK) (BD Biosciences). 
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The following stains were used for flow cytometry: UV Hoechst 33342 cell cycle 
analysis stain (BD Biosciences), Pacific Orange (succinimidyl ester, Life Technologies), 

























Chapter 3: Results 
3.1 DLBCL Subtype is not a Reliable Determinant of Ibrutinib Sensitivity 
Previous studies have reported that the treatment efficacy of the BTK inhibitor 
Ibrutinib can be defined by DLBCL subtype and that only ABC-like patients would benefit 
from treatment103,176. These conclusions also designated that BCR signaling inhibition was 
only a viable strategy in ABC-like patients after studying select cell lines. This standard 
was thus evaluated against a larger cohort of cell lines comprised of 5 ABC-like, 26 GCB-
like, and 7 MCL cell line models (Table 3). Cell line models were plated at equal 
concentrations in triplicate and exposed to a standard range of inhibitor concentrations, 
DMSO control, and blank control. At least three independent experiments were performed 
for each cell line. ED50 values represent the inhibitor concentration at which 50% of cells 
are metabolically inhibited. Thus, a higher ED50 value indicates insensitivity and a lower 
ED50 value indicates sensitivity. The median ED50 was designated as the representative 
value for each cell line and standard error was represented with error bars. Based on 
subtype, the average Ibrutinib ED50 for GCB-like, ABC-like, and MCL cell line groups were 
4.17 r 0.76 PM, 3.79 r 1.66 PM, and 3.16 r 1.73 PM, respectively (Figure 13). We found 
no significant difference between GCB-like, ABC-like, and MCL subtype cell line Ibrutinib 
ED50 sensitivity values (ABC/GCB P = 0.8264, ABC/MCL P = 0.8594, GCB/MCL P = 
0.5363) (Figure 13). These results were in stark in contrast to previous reports that ABC-
like subtype designation was the primary determinant of Ibrutinib sensitivity. Notably, 17 
of the 26 GCB-like cell lines (65.4%) were more sensitive to Ibrutinib than the ABC-like 
cell line average. Moreover, MCL cell lines displayed a higher sensitivity to Ibrutinib 
treatment (3.161 PM) despite lacking the ABC-like designation. MCL cell lines share an 
aggressive BCR signaling profile with DLBCL counterparts, indicating that this 
characteristic, not gene expression, is likely the factor that designates sensitivity. This 
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relationship has been previously observed in studies that included MCL cell lines and 
patients172,174,256. These results indicate that DLBCL subtype classification does not 
represent a definitive measure of Ibrutinib sensitivity. 
 
3.2 DLBCL Cell Lines Display Sensitivity to the PI3Kδ Inhibitor Umbralisib 
After observing Ibrutinib efficacy in GCB-like cell lines, the PIK3CD catalytic 
subunit Inhibitor Umbralisib was examined to see if effective means of BCR inhibition were 
confined to the BTK signaling pathway182,183. PIK3CD represented an attractive target for 
two reasons: the PIK3CD isoform is found predominantly in B-cells, thus sparing off-target 
PI3K isoform binding (PIK3CA and PIK3CB) and the subsequent side effects, and 
because the PI3K signaling pathway represents and emerging therapeutic target for 
patients that don’t respond to BTK inhibition81,124,126.  
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Umbralisib ED50 values were determined for the 38 cell line panel using 
parameters identical to the Ibrutinib assays. The average Umbralisib ED50 for GCB-like, 
ABC-like, and MCL cell line groups were 2.265 r 0.41 PM, 1.130 r 0.44 PM, and 1.74 r 
0.38 PM, respectively (Figure 14). None of the subtypes were significantly more or less 
sensitive to Umbralisib (ABC/GCB P = 0.2493, GCB/MCL P = 0.4754, ABC/MCL P = 
0.3568) (Figure 14). These results were compared side by side to the Ibrutinib results in 
order to visualize cell line sensitivities (Figure 15). These results suggest that Umbralisib 
inhibition of the PIK3CD isoform represents an exciting therapeutic possibility for treating 





3.3 Cell Line Sensitivities to Ibrutinib and Umbralisib are Highly Associated 
Interestingly, the ED50 values for Ibrutinib and Umbralisib were significantly 
correlated (P = 0.0056; R2 = 0.2045) (Figure 16). Cell lines with higher insensitivity to one 
inhibitor were likely insensitive to the other and vice-versa. These results indicated that 
the PI3K arm of the BCR signaling pathway is similarly targetable as the BTK arm of the 
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pathway and that signaling was possibly acting in tandem. The K422 (Umbralisib) and DB 
(Ibrutinib) cell lines were found to be statistical outliers after three independent assays (P 
< 0.001 Z = 4.347, P < 0.001 Z = 3.776). 
 
 
3.4 Barcode Staining does not Influence Intracellular Phosphoflow Measurements 
These results disputed previous reports that BCR signaling inhibition efficacy could 
be predicted by DLBCL subtype classification or the presence of specific mutations, so 
identifying the factors responsible for inhibitor insensitivity was pertinent. We proposed to 
characterize cell lines based on their BCR heavy and light chain isotypes (IgG/IgM and 
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IgO/IgN) and investigate the activation levels of specific BCR signaling through intracellular 
phosphoflow and compare the results to inhibitor sensitivity values. 
First, a barcoding protocol that made it possible to simultaneously assay 16 cell 
line populations was optimized. Dylite 405 (Pacific Blue) and Pacific Orange were diluted 
into three descending concentrations, and DMSO served as a null stain dose. 4 staining 
levels for each dye were used to create a 4 X 4 grid of cell populations. As a control, we 
measured the same cell line in each of the four corners. MFI measurements of intracellular 
components revealed that barcode staining did not change activity level staining (Figure 
17). Staining analysis produced histograms with near identical pS6 activity levels, 






3.5 Surface BCR Isotype is not Predictive of Inhibitor Sensitivity 
Next, 32 cell lines were characterized for their surface heavy chain and light chain 
isotypes through basic flow cytometry experiments. Antibodies specific to IgG, IgM, IgO, 
and IgN were incubated with cell populations of 1x106 and measured with an LSR-II Green 
flow cytometer after applying proper compensation. Following surface isotype 
characterization, IgG and IgM cell lines were compared based on their Ibrutinib and 
Umbralisib sensitivities, and an identical comparison was made between IgO, and IgN cell 
lines. Analysis indicated that heavy chain or light chain surface isotype did not play a role 
determining BCR inhibitor sensitivity (Figure 18). Differences in heavy chain isotypes did 
not reveal a difference in Ibrutinib (P = 0.5080) nor Umbralisib sensitivity (P = 0.1704). 
Light chain isotypes also failed to predict a relationship between Ibrutinib (P = 0.2028) and 







3.6 BCR Pathway Signaling is Variable Among Cell Lines 
Following these results, protocols to determine the relationship between 
intracellular BCR components and inhibitor insensitivity were developed. Levels of 
component activation were assayed after incubating permeabilized and fixated cells with 
phospho-targeted antibodies and measuring levels of fluorescence through flow 
cytometry. We selected a representative cohort of 11 GCB-like, 2 ABC-like, and 2 MCL 
cell lines to assess. Two panels of phosphoflow antibodies were used to simultaneously 
measure the activity of 6 BCR signaling component groups from barcoded cell populations 
(Figure 19). SYK, LYN, BTK, BLNK, and PLCG2 kinases were measured as a collective 
signal labelled “BCR-proximal” due to the inherently low level of signaling each individual 
kinase is responsible for at the beginning of the pathway. 
Analysis revealed stark variation in the intracellular activity levels of BCR signaling 
components between cell lines. Levels of signaling component activation varied widely, 
even within subtype. These results indicated that BCR signaling phenotypes of cell lines 
could be characterized more effectively through intracellular phosphoflow instead of COO 
subtype classification. In fact, GCB-like cell lines such as RL, HT, DHL10, and DHL16 
consistently displayed high levels of signaling in key arenas of the BCR pathway, such as 
BCR-proximal kinases and AKT. Moreover, the highest level of NF-kB signaling was not 
detected in the ABC-like U2932 and HBL1 cell lines, but the GCB-like RL cell line. DHL4 
and DHL6 also displayed above average NF-kB signaling levels, calling the strict ABC-
like chronic BCR signaling phenotype into question. Other results were more consistent 
with the “chronic BCR signaling” phenotype, such as the high levels of STAT 1/3/5 











Unsupervised hierarchal clustering analysis revealed cell line phenotypes based 
on intracellular signaling levels (Figure 20). These results provided important insights 
towards classification of DLBCL cases based on BCR signaling levels. For instance, the 
ABC-like cell lines HBL1 and U2932 clustered within the same family branch, but they 
were most related to the GCB-like HT and RL cell lines, respectively, suggesting that these 
GCB-like cell lines phenotypically presented as aggressive ABC-like DLBCL when 
considering their BCR signaling levels. In addition to defining BCR signaling level 
“families”, the clustering revealed which BCR component relative signaling levels were the 
most related. Activated NF-kB and S6 levels closely mirrored one another, but the 
strongest association was between the BCR-proximal kinase and AKT signaling levels. 
Unsurprisingly, PTEN activity was inversely related to oncogenic BCR kinase signaling 
groups, given its role as a tumor suppressor. PTEN activity was most opposed by NF-kB 
activity. These are the first simultaneously collected intracellular phosphoflow 
measurements of individual BCR-signaling kinase activity levels within a representative 
cohort. These results display a diverse array of signaling levels that are independent of 
subtype, demonstrating that each cell line or tumor is characterized by a unique BCR 
signaling profile. These profiles can serve to define phenotypic families of tumors based 








3.6.1 BCR-proximal and AKT Signaling Activity are Highly Coordinated 
We hypothesized that individual BCR signaling activity profiles could serve to 
elucidate the relationships between individual components and as a predictive factor. In a 
crucial finding, BCR-proximal kinase and AKT signaling activity levels were observed to 
be significantly correlated (P < 0.0001) across all 15 cell lines, indicating that their 
signaling pathways could be acting in tandem and not independently as previously 
assumed (Figure 21). Previous reports have relied on the strict assumption that oncogenic 
B-cells either rely on the BCR-proximal kinase pathway (chronic; ABC-like) or the 
PI3K/AKT pathway (tonic; GCB-like), contrast to these results. Each pathway also 
significantly correlated with STAT 1/3/5 (BCR-prox P < 0.0001, AKT P = 0.0039) and S6 
(BCR-prox P = 0.0239, AKT P = 0.0159) signaling activity (Figure 22). These results 









3.6.2 BCR-proximal and AKT Signaling are Associated with Ibrutinib and Umbralisib 
Insensitivity 
Next, signaling activity measurements against cell line Ibrutinib and Umbralisib 
ED50 sensitivity values were compared. Significant positive correlations between BCR-
proximal and AKT signaling activity and Ibrutinib insensitivity (P = 0.0127, P = 0.0230) we 
observed, as was the same relationship in comparison to Umbralisib sensitivity (P = 
0.0347, P = 0.0188) (Figure 23). These results support the previous association that was 
observed between BCR-prox components and AKT signaling, and they indicate that these 
components likely drive inhibitor sensitivity and response, with both arms of the pathway 
playing a role. These are the first observations to identify a key BCR component 








3.6.3 Loss of PTEN is Associated with Greater AKT/S6 Activity and Insensitivity Towards 
Ibrutinib and Umbralisib 
One of the factors behind increased levels of BCR-prox and AKT signaling appears 
to be the loss of the PTEN tumor suppressor gene, which has a role directly repressing 
PI3K activity through dephosphorylation of IP3 to IP291,123. Relying on PTEN definitions in 
recent literature and lab sequencing and SCNA data, 12 study cell lines were 
characterized as PTEN-deficient (Table 4)123–125. These characterizations were further 
subdivided based on their allelic loss. Possible loss mechanisms included monoallelic 
loss, biallelic loss, and mutation. Four PTEN-deficient cell lines were among those 
assayed for intracellular BCR components activity: RL, HT, DHL10, and U2932. 
Unsurprisingly, mean PTEN activity in deficient cell lines (MFI = 318) was significantly 
lower than that of WT PTEN cell lines (MFI = 1853) (P = 0.0243) (Figure 24). 
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PTEN loss was summarily associated with increased signaling activity downstream 
of its normal role dephosphorylating PIP3 to PIP2. Cell lines with loss of PTEN expression 
were observed to carry 57% greater AKT signaling (P = 0.0370) and 221% greater 
downstream S6 kinase signaling levels (P = 0.0399) (Figure 25). BCR-prox components 
saw a 37% increase in signaling activity in PTEN-deficient cell lines, but this relationship 
did not prove to be significant (P = 0.0996). Collectively, MFI signaling levels were lower 
in WT PTEN cell line AKT, BCR-prox, and S6 (1053; 2087; 5561) compared to PTEN-














Additionally, cell lines with loss of PTEN were associated with insensitivity towards 
both Ibrutinib (P = 0.0470) and Umbralisib (P = 0.0076), a result in line with our initial 
observations of increased intracellular signaling levels. These results agree with previous 
reports that the loss of PTEN allows rampant PI3K/AKT signaling and stymies BCR 
inhibitors, including Ibrutinib despite targeting a seemingly distant kinase. Interestingly, 
they also indicate a close relationship between BCR-proximal kinase signaling, PI3K/AKT 
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signaling, and PTEN loss, further implicating that the pathways are coordinated. However, 
when cell lines were divided based on heterozygous or homozygous PTEN loss the results 
produced separate conclusions. For instance, Ibrutinib insensitivity was significantly 
higher in the 4 cell lines with heterozygous PTEN loss than those with WT PTEN (P = 
0.0004) and homozygous PTEN loss (P = 0.0185) (Figure 25). This awkward result is 
likely due to the smaller sample size incurred by dividing PTEN loss cell lines based on 
functional allele number (4 heterozygous and 8 homozygous). Umbralisib insensitivity was 
significantly higher in cell lines with homozygous PTEN loss than in WT counterparts (P = 
0.0030) and nearly so in comparison to cell lines with heterozygous PTEN loss (P = 
0.0708) (Figure 25). Loss intensity plays a clear role in response to BCR inhibition, and 
further work is warranted to uncover the molecular underpinnings. 
These results are the first to show that BCR inhibitor insensitivity is associated with 
higher levels of signaling in the BCR-proximal components and AKT, which appear to be 
coordinated. Both pathways, but especially PI3K/AKT/S6, appear dependent on PTEN 
status. These results also provide the first evidence that DLBCL sensitivity to BCR 
inhibitors such as Ibrutinib is determined by the level of BCR signaling within these 
components, in contrast to previous reports that subtype or BCR activating mutations were 
responsible. These results also corroborate the increasingly clear role that PTEN status 
plays in DLBCL second-line therapy response and provide justification for targeting BTK 
and PIK3CD in ABC-like and GCB-like DLBCL given the key role that both pathways 
appear to play determining sensitivity. 
 
3.7 Combination of Ibrutinib and Umbralisib Overcomes Insensitivity to Single 
Inhibitors and Exhibits Strong Synergy 
After discovering that high levels of BCR-proximal component and AKT signaling 
were responsible for inhibitor insensitivity, Ibrutinib and Umbralisib were combined in vitro 
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to examine if there was a synergistic relationship. Synergy was initially assayed between 
the GCB-like cell lines DoHH2 and FSCCL. Ibrutinib and Umbralisib doses were based on 
the cell line ED50 values and set against one another in combinations (Figure 26). After 
normalizing for single dosage sensitivities in each treatment, synergistic rates of cell 
inhibition were observed throughout the assay by utilizing the Chou-Talalay median-effect 
method210. Rates of inhibition were considered synergistic when the rate of cellular 
inhibition was greater than the expected additive rate. FSCCL was inhibited beyond the 
additive rate by as high as 18% cell viability reduction in some combinations. DoHH2 also 
displayed consistent rates of synergy that were approximately 5% higher than expected, 
with some combinations closer to 10%. Across all of the treatments, synergy was 


















Following these results, a cohort of 9 cell lines consisting of at least 2 of each 
subtype (GCB-like, ABC-like, and MCL) was assembled. Dose ranges for single-agent 
and combination assays were based upon previously assayed cell line ED50 values, (X = 
ED50). Initially, the PTEN-deficient GCB-like RL and Ly1 cell lines and the ABC-like 
U2932 cell line were assayed. Strong combination synergy was observed for each cell 
line, with synergistic levels of cell inhibition beyond additive levels present (Figure 27). 
Synergy levels beyond 15% of the additive rate of inhibition were observed over four sets 
of doses for each cell line. These results indicated that this combination was capable of 
overcoming increased levels of signaling resulting from the loss of PTEN. 
 
Following these results, the Chou-Talalay median-effect plot method and 
corresponding Compusyn software were used to calculate synergy between the 
compounds. ED50-individualized levels of inhibition for all 9 additional cell lines were 
generated, and resulting CI values were compared. CI values measure levels of synergy 
across levels of cellular inhibition between 0.05 and 0.97, relative to DMSO controls210. CI 
values below 1.0 were considered synergistic, and values at or below 0.5 were considered 
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strongly synergistic. Ibrutinib and Umbralisib combinations displayed strong synergy in all 
9 cell lines models that were examined (Figure 28). While mean CI values hovered near 
0.5, synergy was amplified as the fraction of cells affected increased towards the 0.90 to 
0.97 range. This serves as an important indication that the combination is highly 
synergistic at potential treatment ratios210. As rates of inhibition increased, the ABC-like 
cell lines HBL1 and U2932 displayed the strongest potential for synergy. Moreover, the 
PTEN-deficient GCB-like cell lines DB, RL, and Ly1 displayed similarly dramatic 
responses, adding evidence to the argument that GCB-like cell lines and possibly patients 
would be candidates for therapy, regardless of PTEN status. MCL cell lines also displayed 
strong synergy, but the results were less intense than the ABC-like and GCB-like cell lines 
at higher rates of inhibition. The synergistic relationship between both compounds was 














Succeeding these results, the Drug Reduction Index (DRI) was calculated for 
several cell lines. The DRI is a measure of how many folds the dose of each inhibitor in a 
synergistic combination may be reduced at a given effect level compared with the doses 
of each inhibitor if dosed alone. The reduced dose that will reduce toxicity at the increased 
effect would lead to clinical benefits. A DRI = 1.0 value indicates no dose reduction, 
whereas DRI > 1.0 and DRI < 1.0 values indicate favorable and unfavorable dose-
reduction, respectively. Positive DRI values were observed in all GCB-like, ABC-like, and 
MCL cell lines when treated in combination (Figure 29). This relationship was consistent 
whether a given cell line was sensitive to single agent treatment or not. GCB-like DoHH2, 
Ly1, RL, and DB and ABC-like HBL1 and U2932 cell lines were all highlighted for their 
beneficial DRI values. DRI values above 2.0 have the potential to reduced dosage for 
patients when treated with combination. Average DRI reflected strong dose reduction 
possibility when treating GCB-like or ABC-like cell lines, but certain dosages elicited 
stronger DRI responses than others, depending on the cell line. Ibrutinib dose reduction 
indexes of 20-fold were observed in DoHH2 and U2932. Even DB, the most Ibrutinib-
insensitive cell line, displayed high synergy and approximately 4.0 DRI values when 
treated in combination at medium doses, revealing potential for overcoming insensitivity 
in the most difficult cell lines (Figure 29). These results highlighted the promising clinical 












3.7.1 Rates of Cellular Apoptosis Reflect Cell Synergy Results  
Next, rates of cellular inhibition observed using the Alamar Blue assay needed to 
be confirmed to be reflective of cellular apoptosis. Hoechst cell cycle staining assays 
measured with flow cytometry were used to calculate the rate of cellular apoptosis through 
the quantification of sub-G1 events. DMSO controls, Ibrutinib and Umbralisib ED25 single 
doses, and a combination dose were applied to DHL4 and DHL6 cell lines and incubated 
for 96 hours. Rates of cellular apoptosis were observed to be largely above a predictive 
additive response to single inhibitors in the combination (Figure 30). The 54.59% rate of 
apoptosis observed in DHL4 when treated with combination was greater than the additive 
potential of both single doses combined (Ibrutinib 13.80%, Umbralisib 14.86%). Similarly, 
DHL6 rates of apoptosis were greater in the combination (31.11%) than the additive sum 
of the individual doses (Ibrutinib 16.10%, Umbralisib 4.89%). Pairing these strong CI value 
and apoptosis measurements, a synergistic relationship between Ibrutinib and Umbralisib 
was confidently observed, and this relationship could be applied to patients with 





3.8 Transcription Factors are Targeted by DNA Copy Number Gains in DLBCL 
The GISTIC2.0 algorithm was utilized to analyze high-resolution DNA copy number 
profiles from 673 DLBCL tumors in order to uncover the molecular driver mechanisms of 
BCR inhibitor insensitivity in DLBCL 247. This algorithm integrates the frequency of 
alterations across a cohort, and the magnitude of these alterations, to allow the 
identification of statistically significant regions of DNA copy number gain or loss. The 
‘peak’ of each alteration is defined as the smallest region with the highest significance of 
DNA copy gain/loss and contains a minimal set of genes that likely includes the target(s) 
that drive the alteration. When applied to the normalized set of 673 DLBCL profiles, this 
method identified a total of 13 significant DNA copy number gains that contained 770 
genes in their peaks and 22 significant DNA copy number losses that contained 1450 
genes in their peaks (Figure 31). Lesions were summarized based on location (Table 5). 
Among the 673 patients, the most frequent regions of amplification were 18q21 (f = 0.232, 
Q = 2.93E-11), 7q21.3 (f = 0.189, Q = 0.0356), and 1q32.1 (f = 0.180, Q = 0.00073). The 
most frequent regions of deletion were 6q21 (f = 0.180, Q = 2.93E-48), 6q23.3 (f = 0.189, 
Q = 3.93E-36), and 17p13.2 (f = 0.128, Q = 2.38E-11) (Figure 32). However, significant 













The peaks of SCNAs identified by GISTIC contain one or more likely driver genes 
of each SCNA but are also likely to contain passenger genes. To delineate between driver 
and passenger genes, an integrative analysis of 249 tumors with matched DNA copy 
number and gene expression microarray data was performed. This analysis identified 632 
genes with significantly reduced gene transcript abundance in tumors with DNA copy 
number loss at GISTIC peaks compared to tumors without (FDR Q-value < 0.25) and 
identified 435 genes with significantly higher gene transcript abundance in tumors with 
DNA copy number gain at a GISTIC peak compared to tumors without (FDR Q-value < 





Among these genes were well described targets of DNA copy number alterations 
in DLBCL, such as copy number losses with reduced expression of TP53 (17p13), PRDM1 
(6q21), TNFAIP3 (6q23), B2M (15q15), PTEN (10q24) and RB1 (13q14), and gains with 
increased expression of REL (2p15), BCL6 (3q27), SPIB (19p13), BCL11A (2p16) and 
MDM2 (12q15). To identify cellular processes that are significantly altered by SCNAs, 
hypergeometric enrichment analysis of genes that were targeted by DNA copy number 
loss or gain was performed. Analysis revealed a significant enrichment of cancer hallmark 
characteristics such as apoptosis and proliferation among genes targeted by DNA copy 
number loss, in line with frequently observed lesions in a variety of malignancies (Figure 
34)257. However, analysis of the genes targeted by DNA copy number gain revealed a 
unique enrichment of genes possessing transcription factor activity. The most highly 
significant enrichments were ‘Transcription Factor Activity, sequence-specific DNA 
binding’ and ‘Nucleic acid binding transcription factor’ gene ontologies (FDR < 0.001) that 
each included 58 unique genes that were targeted by DNA copy gain and showed an 
associated increase in transcript abundance in DLBCL. This highlighted SCNA of 










3.9 The DNA Copy Number Landscape in B-Cell Malignancies Includes Alterations of 
Multiple Developmentally Regulated Transcription Factors 
Due to the potentially important role of transcription factor DNA copy number 
alterations in DLBCL and the role of transcription factor networks in regulating B-cell 
differentiation, the DNA copy number landscape of other B-cell malignancies that align 
with different stages of B-cell differentiation was explored. All subtypes of B-cell 
malignancy for which high-resolution DNA copy number data from ≥100 tumors could be 
collected were included. This encompassed B-cell acute lymphoblastic leukemia (B-ALL, 
n = 534), follicular lymphoma (FL, n = 368), splenic/nodal marginal zone lymphoma (MZL, 
n=295), mantle cell lymphoma (MCL, n = 206), chronic lymphocytic leukemia (CLL, n = 
544), and multiple myeloma (MM, n=559) (Figure 35). These malignancies show 
contrasting DNA copy number landscapes at the level of aneusomies and arm-level gains 
and losses, encouraging individual analysis using GISTIC rather than collective analysis. 
For example, B-ALL and MM tumors each showed patterns of hyperdiploidy, but these 
targeted alternate chromosomes in each disease. Analysis of data from each individual 
disease using GISTIC highlighted varying levels of genomic complexity and different 
peaks of DNA copy number gain and loss. Focal, arm-level SCNAs were observed to be 
less frequent than broad, chromosome-level SCNAs, but GISTIC2.0 is primarily driven by 
the presence of these focal SCNAs, since they are likely selected for and contain potential 












Importantly, DNA copy number alterations of multiple transcription factors that 
have been previously implicated in regulating B-cell development were observed (Figure 
37). These included those that have been previously described to be targeted by SCNAs, 
such as IKZF1, REL, PRDM1 (BLIMP1), BCL6, SPIB, and MYC 34,122,129,215,258. In addition, 
novel DNA copy number alterations of transcription that have a defined role in B-cell 
development were identified, such as loss of POU2AF1 (OBF1), NKX3-1, NKX3-2 and 
IRF8, and gains of PBX1, IRF4, and TCF4 (E2-2)39,48,49,54,65. The analysis of an additional 
set of T-cell malignancies (n = 261), myeloid (n = 272), and solid tumors (n = 1510) allowed 
for SCNA classification as either disease-specific, B-cell-specific, lymphoid-specific, or 
multi-cancer alterations. This extended upon prior descriptions of genetic alterations of 
transcription factors as key events in lymphomagenesis, and highlighted transcriptional 






3.10 Co-Segregating Transcription Factor Alterations are Associated with Cell of Origin 
Subtype and Poor Outcome in DLBCL 
The observation of different patterns of transcription factor alteration across 
subtypes of B-cell malignancies that align with diverse stages of B-cell development led 
us to hypothesize that such alterations may also contribute to the etiology of the GCB-like 
and ABC-like molecular subtypes of DLBCL. To identify characteristic patterns of SCNAs 
across DLBCL tumors, unsupervised hierarchical clustering of SCNAs that were present 
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in ≥10% of DLBCL tumors (13 gains and 22 losses) and tumors that possessed ≥2 SCNAs 
was performed (n = 481) (Figure 38). As expected, SCNAs located on the same 
chromosome, but identified as unique GISTIC2.0 peaks, often co-segregate. This is driven 
by tumors that possess broad SCNAs, including arm-level gains/losses and aneuploidies, 
which may span multiple GISTIC2.0 peaks. The peaks are often defined by a subset of 
cases that possess focal copy number gain/loss over the smaller region and likely define 
targets of both focal and broad SCNAs involving that chromosome. In addition to those on 
the same chromosome, co-segregation between DNA copy number gains on 3 different 
chromosomes was observed; 3q27.2, 18q21.31, and 19p13.3 (Figure 38). These 
alterations have previously been defined as targeting the BCL6 transcription factor, the 








COO subtype classification was performed on the 249 samples with matched gene 
expression microarray and DNA copy number data and identified associations between 
the GCB-like or ABC-like subtypes and the presence of each SCNA using a Fisher test. 
This revealed that the three co-segregating DNA copy number gains at 3q27, 18q21 and 
19p13 were also significantly associated with the ABC-like subtype of DLBCL (Figure 38). 
As this subtype has an inferior prognosis compared to the GCB-like subtype, the 
association between SCNAs and overall survival in cohorts treated with combination 
chemotherapy (CHOP, n = 232) or combination chemotherapy with rituximab (R-CHOP, 
n = 197) was also assessed using a log-rank test (Figure 38). Next, COO signature genes 
were arranged in cross-normalized data sets to define patient GEP profiles as ABC-like 
or GCB-like. These results revealed that these lesions were also each associated with the 
ABC-like gene expression profile and an inferior overall survival, as confirmed by Kaplan-







3.11 Gains of 18q21 Target the TCF4 (E2-2) Transcription Factor 
The involvement of the BCL6 transcription factor at 3q27 and the SPIB 
transcription factor at 19p13.3 has been previously demonstrated122,129. Therefore, the 
focus was shifted to 18q21 gains. In contrast to prior observations, GISTIC2.0 analysis 
showed that the most significant peak of DNA copy number gain did not include the BCL2 
oncogene (Figure 40). The 1.58 Mbp peak identified by GISTIC included 3 genes, all of 
which showed significantly increased gene expression in association with these 
alterations. This included TXNL1, WDR7, and the TCF4 transcription factor. The TCF4 
gene has been previously implicated in regulating immunoglobulin gene expression 
through binding of the immunoglobulin enhancer, and we therefore hypothesized that it 
may have a potential role in promoting BCR signaling in ABC-like DLBCL51,65. The 
localization of the GISTIC2.0 peak to the TCF4 rather than BCL2 was driven by the 15% 
of cases with 18q21 DNA copy number gains that included the TCF4 gene but not the 
BCL2 gene. In contrast, only 11% of cases with 18q21 DNA copy number gains included 
the BCL2 gene but not the TCF4 gene. However, the majority of tumors with 18q21 DNA 
copy number gains included both the TCF4 and BCL2 genes (74%), highlighting both of 
these genes as likely important targets of this alteration (Figure 40). This is supported by 
the significant increase in TCF4 expression in ABC-like DLBCL tumors associated with 
18q21 DNA copy number gains (Figure 40). Gain of 18q21 also resulted in significantly 






3.12 TCF4 Gains Are Associated with Increased Immunoglobulin and BCR Component 
Expression 
Chronic activation of immunoglobulin signaling is an important feature of ABC-like 
DLBCL and we hypothesized that TCF4 copy gain may contribute to this phenotype103. To 
investigate this hypothesis, a genome-wide assessment of the transcriptional 
consequences of TCF4 DNA copy number gain was performed. Differential gene 
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expression analysis identified 411 genes with significantly increased gene transcript and 
251 genes with significantly decreased gene transcript abundance associated with TCF4 
gain (Fold-change ≥ 1.2, FDR Q-value < 0.1) (Figure 41). In line with the previous 
implication of TCF4 in regulating immunoglobulin heavy chain expression, significantly 
increased Ig heavy chain µ (IGHM) gene expression in cases with TCF4 DNA copy 
number gain was observed. In addition, increased expression of multiple other signaling 
components downstream of the BCR were observed, including LYN, PIK3CA, BTK, BLNK, 
and CD79A. Analysis of publically-available TCF4 ChIP-Seq data from BPDCN cell lines 
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validated the observed increases in transcription (Figure 42)191. Strong TCF4 binding sites 
with at least 10 reads were found near promoter and enhancer elements of target genes 
despite the BPDCN cell subtype. The 5’ CANNTG 3’ motif was observed within these 
peaks using Integrative Genome Viewer software. 
 
Following these results, comparative marker analysis was performed in order to 
measure differences in gene transcription between 18q21 gain and 18q21 diploid patients. 
This analysis was not restricted to genes within SCNA peaks of gain or loss. After applying 
a stringent filter (Score < 0, Fold-change > 1.2, FDR < 0.05), 578 genes had significant 
increases in transcription and 444 saw significant decreases (Score > 0, Fold-change > 
1.2, FDR < 0.05). 11 of the genes that saw increased transcription were defined within the 
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KEGG BCR signaling pathway annotation260. Increased fold changes in transcript levels 
were observed for several key BCR modulators, such as IGHM (Fold-change = 1.936), 
BLNK (Fold-change = 1.571), CD79B (Fold-change = 1.468), and PIK3CA (Fold-change 
= 1.292) (Figure 43). TCF4 and BCL2 reflected DNA copy number gains with transcript 
Fold-change values of 1.992 and 2.232, respectively, but these increases were 
unsurprising given the genomic gain of their 18q21 locus. These results highlighted TCF4 
as a modulator of the BCR signaling pathway through the transcriptional upregulation of 





3.13 TCF4 Gain Co-segregates with MYD88 and CD79B Mutations in Patients 
BCR signaling is also perturbed by somatic mutations of CARD11, CD79B and 
MYD88 in ABC-like DLBCL, and the relative representation of these alterations may affect 
responses to inhibitors of the BCR signaling pathway such as Ibrutinib102,127,261. Therefore, 
the representation of these alterations in an additional cohort of 124 DLBCL tumors 
previously interrogated by targeted NGS, for which 70 had available cell of origin subtype 
information was assessed. Somatic mutations were identified in CARD11 (16%, 20/124), 
CD79B (9%, 11/124) and MYD88 (13%, 16/124) at similar frequencies to prior 
descriptions176. In addition, the CopyWriteR algorithm was utilized to interrogate SCNAs, 
and identified TCF4 gains in 17% (21/124) of cases (Figure 44)262.  
 
Mutations in CARD11 did not appear to associate with either subtype, but 
mutations in CD79B and MYD88 and DNA copy number gains in TCF4 were more 
prevalent in the ABC-like subtype as expected. Using a Fisher test, a significant co-
association between TCF4 gains, CD79B mutations and MYD88 mutations was observed, 
suggesting that these may not be redundant mechanisms for activating BCR signaling but 
may in fact function in tandem. This corresponded with recent data showing that CD79B 
and MYD88 mutations act synergistically to promote BCR signaling. Interestingly, 
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although mutations in CARD11 were not seen to associate with TCF4 gain, 18q21 gain 
patients experienced a fold change increase of 1.457 in CARD11 transcription in 
comparison to diploid 18q21 patients, indicating that TCF4 may still play an active role 
modulating CARD11 expression (Figure 45). In fact, levels of CARD11 and CD79B 
transcription in cases of 18q21 gain were significantly increased in comparison to diploid 
counterparts (P < 0.0001) and corroborated with ChIP-Seq binding peaks at enhancer 
elements, but MYD88 transcript levels remained unaffected by 18q21 gain (P = 0.2838). 
TCF4 gain may not co-occur with CARD11 mutations, but it may play a role as an 
epigenetic modulator. Together, these results suggested that DNA copy number gains of 




3.14 BRD4 Inhibition Depletes TCF4 and Reduces Immunoglobulin and BCR 
Component Expression 
Previous studies showed that TCF4 expression is dependent on BRD4 regulation 
and could be depleted by the BRD4 inhibitor, JQ1190,191. We therefore hypothesized that 
this axis was also active in cases of ABC-like DLBCL with TCF4 gain. In 4 ABC-like DLBCL 
cell lines with corresponding DNA copy number information, 2 with high-level amplification 
of TCF4 (U2932, 7 copies; RI-1, 6 copies), 1 with a single copy gain (TMD8, 3 copies) and 
1 with diploid TCF4 (HBL1, 2 copies) were identified (Figure 46). The protein expression 
of TCF4 correlated with DNA copy number status, with high expression in U2932 and RI-
1, low expression in TMD8, and undetectable expression in HBL1 (Figure 46). Although 
BCL2 was also increased by these DNA copy number gains, the protein level did not 




The effect of the BRD4 inhibitors iBET-151 and JQ1 were evaluated in two cell 
lines with high basal levels associated with TCF4 amplification. The less-specific pan 
BRD/BET inhibitor I-BET151 induced a slight reduction in TCF4 expression, and JQ1 
induced marked reduction in TCF4 expression (Figure 47). The enantiomer of JQ1, JQ1(-
), was used as a control and was not observed to reduce TCF4. In the TCF4 gain cell lines 
U2932 and RI-1, the loss of TCF4 due to 100 nM and 500 nM treatments of JQ1(+) was 
followed by the reduction of key target BCR components that were identified by microarray 
analysis, including BLNK, PIK3CA, and BTK (Figure 47). BLNK reduction was the starkest, 
as levels in U2932 were reduced by approximately 60% and could not be detected in 500 
nM JQ1(+)-treated RI-1 cells. BTK protein levels were moderately reduced by 
approximately 60% following BRD4 inhibition and subsequent loss of TCF4. Levels of 
PIK3CA were also reduced 60% and 75% of normal levels in U2932 and RI-1, 
respectively. The diminished protein expression of these key BCR components highlights 
the master regulator role that TCF4 plays modulating the expression of aggressive 
signaling BCR components. The key target of TCF4, the surface immunoglobulin heavy 




The TCF4-gain cell lines U2932 and RI-1 were analyzed for levels of IgM after 
treatments with the control enantiomer, iBET151, 100 nM, and 500 nM JQ1. Surface IgM 
levels were measured through flow cytometry, and MFI values were calculated after 
analyzing at least 20,000 gated events. The largest reductions of surface IgM were 
observed in the U2932 (4.5-fold) and RI-1 (1.8-fold) for 500 nM JQ1 exposures compared 
to the equivalent concentration of the control compound, JQ1(-) (Figure 48). This is in line 






Changes in protein expression of BCL2 were not observed in response to BRD4 
inhibition, even though this gene was also targeted by DNA copy number gains in these 
cell lines. Notably, the effect on TCF4 also appeared to be independent of MYC because 
the RI-1 cell line that possesses a MYC translocation did not have reduction in MYC 
expression because of BRD4 inhibition, highlighting that the loss of TCF4 or its targets is 
not secondary to MYC reduction. Together, these results suggest that BRD4 inhibition 
may be a potential avenue to inhibit the aberrant expression of TCF4 and its targets in the 




















Chapter 4: Discussion 
4.1 Challenging the ABC-like DLBCL Subtype and BCR Signaling Dogma 
It is well established that targeted inhibitor therapies will play a significant role in 
the future of cancer medicine263. Small molecule inhibitors capable of targeting specific 
kinases vital to the cellular program of a tumor cell while sparing healthy tissue are the 
first step towards achieving a truly personalized treatment. However, research is still 
necessary to fully elucidate the potential and possible consequences of these new and 
exciting therapies. B-cell lymphomas are no exception. Despite the advent of R-CHOP 
and immunotherapies capable of achieving a 50% cure rate, DLBCL patients that 
experience refractory or relapsed disease have a dismal clinical outlook171. Considering 
this patient subset as its own population, second line therapies have only been able to 
generate objective response rates of 26% (7% CR), a median overall survival of 6.3 
months, and a 20% 2-year survival prognosis171. Moreover, significant gains in rate of 
survival has not been realized for over a decade61,167. Even the introduction of CD19 CAR-
T-cells falls short for many of these patients, as patients with aggressive lymphoma do not 
have the necessary 17-21 days available to properly apply this therapy198. With little to no 
curative options currently available to this patient population, we sought to discover novel 
insights and improve clinical outcomes. 
The BTK inhibitor Ibrutinib has generated enthusiasm because of its ability to block 
BCR signaling in several subtypes of lymphoma. Ibrutinib owes its remarkable selectivity 
to the ability to form a covalent bond with a conserved cysteine residue (C481) on BTK173. 
The pharmacokinetic characteristics of Ibrutinib are so powerful that it can bind >99% of 
available BTK molecules within 2-3 hours, resulting in durable and complete inhibition174. 
Additionally, Ibrutinib is rapidly absorbed and eliminated which relieves off-target effects, 
and is orally bioavailable. Here, we aim to define which refractory and relapsed lymphoma 
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patients would benefit from this therapy as well as clinically actionable combinations of 
Ibrutinib and PI3K inhibitors that could serve to increase response rates and circumvent 
possible mechanisms of resistance. 
Landmark studies used Gene Expression Profile (GEP) data to designate two 
major subtypes of DLBCL: GCB-like and ABC-like. Well-defined sets of genes were 
measured for their expression levels to determine COO90,106,264. ABC-like DLBCL cases 
were found to be associated with the genetic phenotype of an activated B-cell, to be more 
aggressive, and to carry an inferior prognosis90. Sequencing data began to add to the 
ABC-like definition, as mutations in BCR signaling component genes or modulators were 
found to be prevalent in this subtype103. Furthermore, BCR signaling was found to play a 
central role driving ABC-like lymphomagenesis through aggressive, chronic levels of 
signaling that culminate in the activation of the NF-kB, MEK/ERK, and mTOR/S6 
pathways103. Under normal conditions, the pro-survival and proliferation programs 
stimulated through BCR signaling are vital for proper B-cell selection and development5. 
Ibrutinib was introduced to stymie this pathway through the inhibition of the central 
BTK gene. Initially, Ibrutinib was found to successfully treat patients with aggressive forms 
of CLL and MCL despite adverse effects in several cases174. With ABC-like DLBCL defined 
as the subtype with chronic BCR signaling and GCB-like only defined as bearing less-
aggressive “tonic” BCR signaling, the inhibitor was introduced against the former103,176. 
Results were promising and displayed strong efficacy in ABC-like patients, despite 
avenues of resistance presented by BTK cysteine mutations that prevented binding, 
overreaction of the PI3K pathway catalytic subunits (PIK3CA/PIK3CD), and activating 
mutations in MYD88 and CARD11156. However, much of the work downplayed the 
effectiveness that Ibrutinib had treating GCB-like DLBCL, the less-aggressive subtype 
characterized by a genetic phenotype resembling a germinal center B-cell. Definitions 
based on subtype, mutation status, and levels of BCR signaling isolated GCB-like patients 
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as ineligible for Ibrutinib therapy. GCB-like patients with relapsed or refractory disease 
after receiving R-CHOP experience the same poor prognosis as refractory or relapsed 
ABC-like patients, but they do not have an available second line of therapy after being 
deemed ineligible for BCR inhibitors171. We decided to revisit these definitions aiming to 
uncover new therapeutic possibilities. 
Our study was carried out across over 38 Non-Hodgkin's Lymphoma cell lines of 
varying subtype and mutation status, and while previous characterizations are not to be 
dismissed, our large population of cell lines proved to be a powerful statistical tool for 
uncovering DLBCL response to BCR inhibitors. Previous studies only utilized 5-8 cell lines 
when making conclusions. Our study thus represented an opportunity for strong statistical 
analysis across a spectrum of categorical variables such as subtype, mutation status, 
inhibitor sensitivity, and BCR component signaling activity. We sought to elucidate the 
functionality of BCR inhibitor therapy across DLBCL to improve clinical outcomes and 
discover unexplored avenues for those patients without any remaining therapeutic 
options. 
The molecular classification of DLBCL by COO analysis and presence of activating 
BCR signaling mutations have been used to justify eligibility for Ibrutinib or other BCR 
inhibitor therapies. Strictly speaking, GCB-like DLBCL was defined as unresponsive to 
these therapies based on a cohort of only 20 patients. Despite median GCB-like PFS 
responses of 1.31 months, ABC-like responses were only slightly higher at 2.01 months176. 
Additionally, of 11 evaluable GCB-like tumors, 5 displayed clinical response and reduction 
(45.5%). These results closely compared to the ABC-like response, in which 21 patients 
saw a reduction in tumor volume out of 32 (65.6%). Furthermore, clinical overall survival 
of ABC-like patients was only 30% at 21 months alongside 20% of GCB-like patients, 
indicating that a black and white interpretation of Ibrutinib response based on subtype was 
not warranted. In fact, these results add to the case that refractory or relapsed DLBCL 
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patients represent a collective population capable of being studied as its own. Mutation 
status of CARD11, CD79B, and MYD88 were also used to define responsiveness, with 
MYD88-only and CARD11-only mutants designated as unresponsive prognostic 
determinants. These interpretations were made using 8 cell line models and were not able 
to reflect a broad relationship. Our work aimed to critique these conclusions and discover 
untapped sources of therapeutic benefit for GCB-like DLBCL patients. 
Previous conclusions that sensitivity to Ibrutinib was determined by DLBCL 
subtype and the presence of mutations affecting BCR signaling were not supported when 
tested in larger cohorts. For instance, after determining ED50 values for all 38 cell lines, 
we did not observe a significant difference in sensitivity between GCB-like and ABC-like 
cell lines. ABC-like cell lines were theorized to be more sensitive, but numerous GCB-like 
cell lines displayed greater sensitivity to Ibrutinib than ABC-like counterparts or the mean 
ABC-like ED50 value. We theorized that a subset of GCB-like patients would thus be able 
to benefit from Ibrutinib or BCR inhibitor treatment, especially if we could delineate what 
was leading to insensitivity and how to overcome it. We theorized that BCR signaling could 
be playing a larger role in refractory or relapsed GCB-like patients than previously 
assumed, as different molecular phenotypes did not appear to serve as a key designating 
factor. 
Another previous conclusion was that insensitivity or sensitivity could stem from 
activating mutations in key BCR signaling components, namely CARD11, CD79B, and 
MYD88. CARD11 activates the IKKE kinase, which goes on to modulate NF-kB signaling. 
Mutations in the CARD11 coiled-coil domain enhance this effect127. CD79B is an adaptor 
molecule to the BCR heavy chain and relays signaling to the entire BCR pathway after 
phosphorylation of its ITAM regions. Activating mutations in these regions lead to 
constitutive signaling throughout the pathway103. MYD88 activating mutations amplify its 
modulatory effects of IKKE and NF-kB and is somewhat independent of BCR signaling102. 
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We compared Ibrutinib ED50 sensitivity values across WT and mutant cell lines to 
evaluate these conclusions. We observed that there was not a significant sensitivity 
difference between WT and mutant cell lines when considering CARD11 or MYD88 
mutations (Ancillary Figure 3). However, we did not have enough MYD88 (4/38), CARD11 
(3/38), nor CD79B (2/38) mutant cell lines to make a strong enough conclusion.  
Moreover, the ABC-like cell lines HBL1 and TMD8 shared MYD88/CD79B 
mutation profiles and were thus predicted to share Ibrutinib sensitivity. However, the cell 
lines responded very differently. HBL1 garnered an insensitive 7.751 μM Ibrutinib ED50 
while TMD8 was one of the most sensitive cell lines with an ED50 of 0.201 μM (Ancillary 
Figure 4). However, comparisons between isogenic cell lines with engineered changes 
would provide better evidence of this relationship. We also observed that while mutations 
in BCR signaling components are enriched in ABC-like cell lines, they are not exclusive 
(Ancillary Figure 1). GCB-like cell lines are capable of incurring BCR mutations, and when 
they are accounted for, there are still no significant differences in sensitivity.  
We concluded that DLBCL subtype classification was not a reliable Ibrutinib 
sensitivity or insensitivity determinant. We also observed efficacious responses to Ibrutinib 
in GCB-like cell lines, indicating the potential therapies targeting BCR signaling in this 
subtype. These findings opened new questions regarding the role of BCR signaling in 
subtypes outside of ABC-like DLBCL, but most importantly, they indicated that it is 
irresponsible to deny a possible therapy to GCB-like patients with relapsed or refractory 
disease. 
In order to ensure that our results were not isolated to Ibrutinib or BTK inhibition, 
we sought to compare our results against another BCR inhibitor. We selected the novel, 
“next-generation” PIK3CD inhibitor Umbralisib owing to its clinical efficacy, safety profile, 
and orally-bioavailable once-a-day application. In comparison to the rival PIK3CD inhibitor 
idelalisib, Umbralisib presents less toxicity, a greater half-life, and greater binding 
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selectivity for the PI3K catalytic subunit PIK3CD isoform183. A cohort of 256 Idelalisib 
patients carried an 11.67% risk of incurring at least one grade 3 or 4 toxicity symptoms, 
while only 4% of 165 Umbralisib patients experienced similar symptoms182. The reduced 
side effects are likely due to the exclusion of the Idelalisib heterocyclic backbone, which 
is known to interact with hepatic enzymes182. We were also eager to see if inhibition of the 
PI3K arm of the BCR signaling pathway would provide new DLBCL insights, especially 
with an isoform-specific inhibitor given the mixed clinical performances of pan-PI3K 
inhibitors. The role of PI3K/AKT signaling in GCB-like DLBCL also warranted further 
studies. 
We assayed all 38 cell line models against Umbralisib using the same dose range 
and parameters of the Ibrutinib assays. Once again, neither subtype classification nor the 
presence of mutations in the BCR signaling pathway were determinants of sensitivity. The 
intense GCB-like cell line response indicated that BCR signaling was playing a stronger 
than expected role in GCB-like DLBCL, at least within the PI3K arm of the pathway. 
Interestingly, we also observed that the ED50 sensitivity values for Ibrutinib and 
Umbralisib were significantly correlated. These results indicated that the cellular 
mechanisms responsible for determining BTK/PI3K inhibition sensitivity were associated 
with one another. We proposed that the BTK/PI3K pathways could be coordinated and 
less independent of one another than previously assumed, since insensitivity in one 
pathway was so strongly associated with insensitivity in the other. A hypothesis based on 
the the prospect of tandem BCR signaling put us at odds with the conventional chronic vs 
tonic BCR signaling model often used to define ABC-like and GCB-like DLBCL cases, 
respectively, but we sought to discover if these pathways held the key to BCR inhibitor 





4.2 Identifying the Source of BCR Inhibitor Insensitivity 
Despite measuring inhibitor sensitivities of two separate BCR signaling pathways 
against established variables such as DLBCL COO subtype and mutations, we were 
unable to determine the source of BCR inhibitor insensitivity in cell lines. We hypothesized 
that the intracellular activity/phosphorylation level of BCR components could be a 
determinant of sensitivity. We assembled three panels of antibodies capable of 
characterizing cell line surface immunoglobulin isotypes and measuring the intracellular 
phosphorylation levels of each noted BCR component. Components were measured 
simultaneously using our unique 4 X 4 cell line population barcoding system. Surface 
immunoglobulin isotype was not a significant determinant of inhibitor sensitivity, but the 
15 cell lines that were measured for their activity levels through intracellular phosphoflow 
and granted us a comprehensive visualization of BCR signaling activity. One of the striking 
characteristics of the signaling assay was the varied levels of signaling across a spectrum 
of BCR components, indicating that signaling phenotype is fluid. Moreover, we did not 
observe strictly higher levels of signaling in ABC-like lines as compared to GCB-like. For 
instance, the GCB-like RL cell line displayed the highest levels of NF-kB signaling, and 
counterpart cell lines HT and DHL10 displayed consistently high levels of signaling in 
kinase pathways as well. These results led us to perform an unsupervised hierarchal 
analysis of cell lines based on their signaling levels for each staining target. The result 
was a tumor phylogeny, clustered by signaling profiles. This analysis allowed us to 
observe cell line BCR signaling phenotypes, along with related families. The analysis was 
also performed on specific signaling targets, finding that BCR-proximal kinase and AKT 
activity were the most highly related of the 6 signaling targets that were analyzed, while 
PTEN and NF-kB activity levels were most opposed to one another. This signaling cohort 
represents the first opportunity to define DLBCL tumors based on the BCR signaling 
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components, regardless of COO classification or mutation status. We are particularly 
excited about further defining these results in larger cohorts. 
BCR-proximal kinase (SYK, LYN, BTK, and BLNK) activity levels were measured 
together and were significantly associated with levels of AKT activity. High activity in one 
pathway was reflected by high activity in the other for a given cell line. This finding was 
particularly strong, and it corroborated our previous stipulations that these pathways were 
being activated in accord, not independently. Both signals also significantly correlated with 
STAT 1/3/5 and S6 phosphorylation activity. S6 is downstream of AKT and therefore does 
not represent a surprising result, but increased STAT signaling along with BCR-prox and 
AKT activity invites the possibility of an expanded network of coordinated signaling within 
the BCR pathway that calls for more work to fully elucidate. We are the first to report the 
tandem activation patterns of the BTK and AKT pathway arms, and these findings warrant 
a revalidation of the black and white “chronic” and “tonic” signaling definitions previously 
attributed to the ABC-like and GCB-like subtypes, respectively.  
Uncovering this linkage led to the key finding of this report: higher levels of 
insensitivity to either Ibrutinib or Umbralisib were significantly associated with increased 
levels of signaling in BCR-proximal kinases and AKT. Higher levels of phosphorylation 
activity in either pathway was an indicator of insensitivity to either inhibitor. The cause of 
BCR inhibitor insensitivity can thus be attributed to higher levels of signaling in these 
kinases, according to these data. This finding supports the original observation that 
Ibrutinib and Umbralisib sensitivities were highly associated as well. The coordination of 
these pathways serves as a novel insight towards BCR biology, as well as a potential 
means of resistance of signal inhibitor treatments. 
Furthermore, we observed significantly higher levels of AKT/S6 signaling activity 
and insensitivity to Ibrutinib and Umbralisib in cell lines with PTEN loss. PTEN is a negative 
regulator of the PI3K pathway, and therefore rampant signaling can proceed in its 
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absence, leading to insensitivity and a poor prognosis123. Perhaps most interesting, PTEN 
activity was most opposed to NF-kB signaling, once again highlighting a connection 
between two oncogenic BCR signaling pathways. PTEN loss could allow unlimited BTK 
recruitment via PIP3 and subsequent NF-kB activity. These results have a clinical 
application, as patients with higher levels of BCR component phosphorylation activity or 
PTEN loss may not respond to the same dosage as a patient with lower BCR activity and 
vice versa. BCR-prox and AKT activity levels thus represent a scale of positive to negative 
likelihoods of inhibitor response and could be useful for predicting efficacious doses. 
Patient biopsy analysis could be particularly helpful for designating therapy under these 
circumstances. Most importantly, classification of sensitive and insensitive patients would 
not be reliant upon COO subtype or the presence of BCR mutations. Instead, it could be 
measured by directly assessing BCR signaling component activity levels. We look forward 
to measuring the activity levels of these components through biopsy samples from our 
ongoing clinical trial patients. 
After identifying the source of BCR inhibitor insensitivity, we sought to engineer a 
method for overcoming greater signaling. We proposed combining Ibrutinib and 
Umbralisib and assessing synergy. High tandem activity of BCR-proximal kinases and 
AKT called for a tandem therapy. Given the powerful coordination between both pathways, 
a single inhibitor would only be able to limit one, thus allowing rampant BCR signaling to 
proceed through the other given our coordinated signaling results. Recent work has even 
highlighted the potential role that BCR-prox components play activating the PIK3CA 
isoform when inhibited, calling for a combined therapy265. Although GCB-like cell lines 
were predicted as poor responders to BCR inhibitors by previous reports, we quickly 
observed synergy once we assayed the inhibitors together in the DoHH2 and FSCCL 
GCB-like cell lines. Synergy was observed across the assay doses with specific 
combinations yielding the greatest levels. We assessed 9 total cell lines against both 
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inhibitors and observed strong synergy in each. We also made sure to assess our 
combination against PTEN-deficient cell lines such as U2932, RL, and Ly1 and observed 
similarly promising results, indicating that this combination was capable of overcoming the 
loss of a key tumor-suppressor responsible for determining AKT signaling levels. 
Interestingly, we observed some of our strongest results in GCB-like cell lines. GCB-like 
reliance on PI3K pathway is an emerging hallmark, but our results define a clear role in 
this subtype and highlight a new therapeutically actionable pathway. High BCR signaling 
was even overcome through combination in the insensitive cell lines DB, HBL1, and RL. 
Refractory or relapsed DLBCL patients could thus be potential beneficiaries of a 
combination that accounts for both major BCR signaling pathways. Additionally, cell lines 
were predicted to have their highest levels of synergy at the highest levels of inhibition 
(80% – 97% inhibition), which serves as a predictor of positive clinical efficacy210. These 
results were bolstered by large Dose Reduction Index (DRI) values. These values 
indicated the potential for reduced doses of inhibitors when applied in combination instead 
of as single inhibitors. High DRI values and low Combination Index values across ABC-
like, GCB-like, and MCL cell lines display a promising clinical outlook for this combination, 
especially when considering the possibility of reduced patient side effects owing to 
reduced dosage when treated with combination and the tremendous safety profile of 
Umbralisib. 
Recent work has stated the need for dual PI3K PIK3CA/PIK3CD inhibitors despite 
the increased risk of toxicity125. One set of results indicated that ABC-like DLBCL cells 
treated with PIK3CD inhibitor were able to activate PIK3CA and restore signaling265. While 
these results serve to validate our arguments that BCR-proximal components are capable 
of overcoming single inhibitor PIK3CD inhibition, they are not supported by our in vitro 
inhibition findings. The previous work that called for dual PI3K α/δ inhibition observed that 
the PIK3CD inhibitor Idelalisib failed to achieve 50% inhibition in these cell lines despite 
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treatments as high as 5 μM and the presence of BCR signaling mutations125. These 
discrepancies suggest that the use of a less effective inhibitor to invalidate PIK3CD single 
agent inhibition should not disqualify newer PIK3CD -specific inhibitors. Additionally, dual 
PI3K α/δ inhibitors such as copanlisib have been shown to have dramatic in vitro effects, 
but they have yet to perform as well in the clinic due to harsh side effects caused by off-
target PIK3CA inhibition. In fact, the study documented that the weight loss in mouse 
models treated with copanlisib was as high as 20% after only 14 days of treatment, while 
mice treated with PIK3CD inhibitors only experienced 5% weight loss125. PIK3CD inhibitors 
have proven to be a safer clinical choice than PI3K α/δ inhibitors given the specific 
lymphoid role of PIK3CD. PIK3CA is a ubiquitous PI3K p110 catalytic isoform found in 
tissues across the body, and thus these inhibitors tend to produce severe side effects. The 
role of PIK3CA in ABC-like DLBCL biology is not to be discounted however, as ratios 
between the isoforms can be different in each cell line. In fact, our cell line inhibition results 
agree with the finding that high α/δ ratio ABC-like cell lines were more insensitive to 
PIK3CD inhibition than low α/δ ratio counterparts125. We observed that the high PI3K α/δ 
ratio ABC-like cell line U2932 (2.609 μM) was less sensitive to Umbralisib than the medium 
PI3K α/δ ratio HBL1 (1.572 μM) cell line, which was subsequently less sensitive to 
Umbralisib than the low PI3K α/δ ratio counterpart and TMD8 (0.5708 μM). These results 
suggest that PI3K α/δ ratio could serve as a clinical determinant of Umbralisib efficacy in 
the future. These observations are grounded in patient data that reported higher PI3K α/δ 
ratios in stage III/IV patients (66%) than those with stage I/II disease (32%)125. Umbralisib 
and PIK3CD inhibition will play a prominent role in the treatment of refractory and relapsed 
DLBCL patients, but uncovering new mechanisms for inhibiting PIK3CA while maintaining 
patient health remains an important step towards achieving this goal. 
Collectively, these results demonstrate the clear role BCR signaling plays in GCB-
like DLBCL along with the ABC subtype. Our results exhibit that neither subtype nor 
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mutation status should bar refractory or relapsed patients from second line therapies that 
target the BCR signaling pathway. Moreover, we uncovered that response to BCR 
inhibitors is directly associated with BCR-proximal kinase and AKT signaling levels. These 
factors can be utilized as a means for predicting patient response in favor of subtype of 
mutations, as well as PI3K α/δ ratios and PTEN status. Patient insensitivity to BCR 
inhibitors can also be overcome through the synergistic combination of Ibrutinib and 
Umbralisib, which targets both key pathways. The future of second line BCR signaling 
therapies carries strong potential for relapsed or refractory DLBCL patients, and we have 
opened an ongoing phase II clinical trial to assess the in vivo efficacy of this combination 
that does not discriminate on subtype. 
In conclusion, we have provided evidence for a change in how the refractory and 
relapsed DLBCL patient population is assessed and treated. Chronic vs. tonic signaling 
profiles may not be strictly determined by subtype or mutations as previously reported. 
We incorporate new findings that highlight BCR-proximal kinases and the PI3K/AKT 
pathway as the most promising targets moving forward and suggest that future therapies 
avoid black and white classification criteria and target these pathways in combination 
given the striking connection that we uncovered. 
 
4.3 Characterization of the Novel DLBCL and BCR Signaling Driver: Transcription 
Factor TCF4 
Our results determined that higher levels of coordinated signaling in BCR-proximal 
kinases and AKT resulted in greater insensitivity to BCR inhibitors, but we sought to 
understand the source of this increased signaling. High levels of BCR signaling have been 
previously characterized, but they were determined to be dependent on subtype or 
mutations - conclusions that our results did not support. Understanding the source of this 
increased signaling was key to improving patient response given our findings. 
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 We began with a hypothesis-generating approach by assembling 673 publicly 
available SNP microarray copy number profiles to define the landscape of genomic gains 
and losses across DLBCL. A cumulative analysis of this size had not been performed 
before, and we aimed to uncover molecular driver genes of DLBCL that were previously 
undetectable in smaller studies. The GISTIC2.0 copy number algorithm was uniquely well-
equipped to analyze this large amount of data because unlike other copy number analyses 
it takes magnitude into account along with frequency, generating a G-score capable of 
measuring lesions with greater accuracy247. Genes found within significant peaks are 
assumed to be selected for and thus designated as possible drivers of lymphomagenesis. 
249 of the 673 cases had complimentary GEP profile data, allowing us to take a closer 
look at potential driver genes. One key admonition of our analysis was a lack of epigenetic 
measurements, despite a robust pairing of copy number and expression analyses. 
 Our GISTIC2.0 results provided regions of significant genomic gain (13 peaks) or 
loss (22 peaks) across DLBCL that contain the likely genetic drivers of the disease. Genes 
known to play a role in lymphomagenesis were observed in regions of gain (REL 2p15, 
BCL6 3q27, and SPIB 19p13) and loss (TNFAIP3 6q23, PTEN 10q24, RB1 13q14, and 
TP53 17p13)122,123,128,129. The results of the analysis were essential, but we needed to 
further specify the pool of 2,200 driver gene candidates. Utilizing the 249 SCNA profiles 
with matching GEP data, we performed an integrative analysis to specify which genes 
were not only in regions of gain or loss but also significantly gained or lost expression as 
a result. 632 genes within regions of significant deletion were observed to lose expression 
as well as 435 genes that were within amplified regions and showed increased levels of 
expression. Analysis of these gene sets revealed that the deleted genes were enriched 
for roles in the cell cycle, apoptosis, and the mitotic process - all classical functions of lost 
tumor suppressors257. In contrast, the enrichment analysis of the amplified genes revealed 
a surprising result: DNA binding transcription factor activity. Unique transcription factor 
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perturbations can be observed across B-cell malignancies, but characterizing their activity 
as a major driver of DLBCL represented a novel finding. We are the first to report that 
transcription factors are an enriched target of DNA copy number gains in this disease. 
 In order to validate our results as DLBCL specific, we collected SCNA profile cohort 
from six other lymphoma subtypes (MM, CLL, B-ALL, FL, MZL, and MCL) and interrogated 
corresponding SCNA datasets using GISTIC2.0. While some gain and loss peaks were 
shared, each subtype was characterized with disease specific regions of gain and loss. 
Including DLBCL samples, 3,179 tumor profiles were analyzed, providing us with deep, 
unique insights into the disease biology of each subtype. While we lacked the matching 
GEP profiles for the other subtypes that were used for analysis of DLBCL, transcription 
factors were targeted by SCNAs across the spectrum of B-cell malignancies. Analyzing 
large cohorts of T-cell, Myeloid, non-hematological patient samples allowed us to define 
lesions as disease specific, B-cell specific, lymphoid specific, or as multi-cancer 
alterations. These results highlighted the growing importance of transcription factors in 
lymphoma biology. Future research would be wise to focus on treatments that disrupt the 
malignant programs brought on due to the gain or loss of these targets. 
 With transcription factors identified as key drivers of DLBCL, we next focused on 
the individual lesions in order to identify key genes. Unsupervised hierarchical clustering 
of patient SCNA peaks revealed that amplifications of 3q27, 18q21, and 19p13 clustered 
together and were significantly associated with the ABC-like subtype and a poor prognosis 
following R-CHOP treatment, despite being located on separate chromosomes. BCL6 at 
3q27 and SPIB at 19p13 are within these peaks and known modulators of lymphoma122,129. 
We therefore focused on 18q21. This region contains the hallmark pro-survival oncogene 
BCL2, but closer inspection revealed that DNA copy number gain of the transcription factor 
TCF4 was driving the peak. Moreover, the integrative analysis revealed that TCF4 was 
the most significantly increased gene amongst all DLBCL lesions. While BCL2 still likely 
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maintains a role as a driver, the larger number of tumors analyzed by this study allowed 
us to identify previously unknown targets such as TCF4. GISTIC2.0 identified more focal 
gains of TCF4 than BCL2 as well, indicating stronger selective pressure for TCF4 gain. A 
cooperation between the two key genes is evident, as 74% of tumors with 18q21 gain 
carry both genes, while tumors with DNA copy number gains in TCF4-only and BCL2-only 
represent 15% and 11% of this population, respectively. Thus, both genes likely maintain 
driver roles when gained together but are capable of driving disease development when 
amplified alone. 
 Our ultimate goal was to uncover the factors responsible for increased BCR 
signaling activity, and we sought the answer through differential gene expression analysis. 
In a key finding, we observed that cases with TCF4 gain were significantly associated with 
the increased expression of key BCR signaling components, including the IgH heavy 
chain, BLNK, LYN, BTK, SYK, and PIK3CA. In cases of TCF4 amplification, BCR signaling 
component transcripts were expressed at significantly higher levels compared to the cases 
with diploid TCF4, and the evidence was clear that TCF4 was playing a driving role in 
DLBCL through modulation of the BCR pathway. We propose that increased amounts of 
BCR components and subsequent signaling due to TCF4 gain could lead to higher levels 
of insensitivity that we observed in cell lines and the unfavorable outcome of these patients 
observed in our initial analysis of 18q21 gain patients. The role of TCF4 driving expression 
of the IgH heavy chain is well documented in both normal and tumorigenic settings, and 
more IgH directly leads to more surface immunoglobulin and thus more cross-linking and 
signaling48,49,65. Publicly available ChIP-Seq data provided validation for these 
observations, albeit in a different hematological malignancy (BPDCN)191.  
In order to observe the effects of TCF4 directly, we dosed ABC-like cell lines with 
JQ1 to inhibit BRD4 function, a known transcriptional modulator of TCF4 essential for its 
function. BRD4 inhibition abolished TCF4 protein, and we observed stark losses of surface 
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IgM and the BCR components BLNK, BTK, and PIK3CA. We only observed these 
reductions in cell lines with 18q21 gain, thus reinforcing the driver role TCF4 plays when 
amplified. PIK3CA reduction in response to TCF4 abolishment was particularly revealing, 
as we observed a relationship between higher PIK3CA and Umbralisib insensitivity. This 
represented a powerful finding and supports the role TCF4 plays as a master regulator of 
BCR signaling capable of transcribing the specific components necessary to elude 
therapy. 
TCF4 gain leads to an imbalance that triggers the over activation of its transcription 
targets. Although capable of relying on homodimerization, TCF4 shares a strong 
partnership with the key B-cell development bHLH transcription factor TCF3, and it is 
capable of heterodimerization to promote the transcription of key proliferative genes 
necessary for B-cell development. When the balance of TCF4 protein is disturbed through 
DNA copy number gain, homodimerization may be able to occur in cases that it otherwise 
would not be able to, and transcriptional targets capable of stimulating key signaling 
pathways (such as IgM or BCR components) could lead to lymphomagenesis. This 
mechanism introduces an important question: is TCF4 gain an early clonal founder event 
in tumor evolution, or are successive gains of TCF4 selected for after several initiating 
events have already stimulated lymphomagenesis? This would determine how effective 
therapies targeting TCF4 would be in patients that have tumors reliant on TCF4 gain vs. 
those that acquired it later during advanced disease. Early acquisition of TCF4 could 
trigger premature B-cell activation, hence the association with the ABC-like subtype, and 
it could also set the stage for subsequent oncogenic events that occur after enough 
survival and proliferative programs had been initiated by TCF4. Late acquisition of TCF4 
would still account for the poor R-CHOP response experienced by patients with 18q21 
gain through the modulation of aggressive BCR signaling and subsequent survival 
programs. However, 85% of these patients also incurred gains in BCL2, with 11% of them 
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being BCL2-only gains, so further work would need to identify TCF4 as the primary driver 
of these cases. Whether TCF4 gain is an early or late oncogenic event is an interesting 
question and if addressed could provide key insights towards treating this patient 
population. 
 
4.4 Conclusions and Further Research 
In this dissertation, we have provided a compelling case to re-define chronic BCR 
signaling and its origins in DLBCL. Subtype classification and mutations in BCR signaling 
components play a role, but they do not define patient response to second line therapies 
such as Ibrutinib or Umbralisib. This is especially true in cases of GCB-like lymphoma, 
where patients were being denied these therapeutic options because of black and white 
reports that BCR signaling was only active within the ABC-like subtype, despite a 
demonstrated GCB-like reliance on BCR signaling in a percentage of circumstances. 
Several GCB-like cell lines even displayed some of the higher NF-kB and BCR-proximal 
component signaling levels. In fact, high levels of activity in the BCR-proximal kinases and 
AKT, as defined by intracellular phosphoflow, are the most likely predictive factors of 
disease aggressiveness, not COO subtype. The intense coordination of signaling between 
these pathways represented another novel finding, demonstrating previously unknown 
relationships between BCR-proximal kinases and the PI3K/AKT pathway, as well as a 
distinct relationship between PTEN status and NF-kB signaling and inhibitor insensitivity. 
PTEN status assays alongside levels of BCR component activity could be measured from 
patient samples and potentially used to justify specific doses or predict patient response. 
New findings are beginning to arise and corroborate the key role that the PI3K/mTOR/S6 
pathway plays determining DLBCL biology. Moreover, the role of PI3K in GCB-like DLBCL 
is slowly becoming clearer, adding to the potential of second line therapies that target this 
pathway for patients that otherwise have few options. The results also corroborate the 
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importance of PIK3CA and PTEN in this new vision of BCR signaling, and these 
components must be accounted for when researching future therapies. 
 We also demonstrated that a combination of Ibrutinib and Umbralisib was highly 
synergistic and able to overcome insensitive cell lines. Given that BCR-proximal kinase 
and AKT activity levels are in-sync and play a role determining insensitivity, it is vital to 
target these pathways in aggressive cases of DLBCL. These results buoyed the argument 
that GCB-like patients could benefit from this combination, as those cell lines displayed 
equally encouraging levels of synergy as ABC-like counterparts. Even high PI3KCA-
expressing and PTEN-deficient cell lines displayed strong synergistic responses to the 
combination. However, a devil’s advocate could argue that targeting the SYK or LYN 
initiator kinases would provide a better avenue for therapy than dual inhibition, but the 
poor clinical performance of these inhibitors limits the strength of this aim until safer, more 
effective inhibitors are available68,177. Umbralisib maintains a remarkably safe symptom 
profile, and its cytostatic mechanism pairs well with Ibrutinib’s cytotoxic and 
immunomodulatory functions. Recent work highlighted that Umbralisib efficacy could 
partly be attributed to second-hand inhibition of CK1ε, a trait not shared by its counterpart 
PIK3CD inhibitor Idelalisib. CK1ε inhibition can lead to MYC silencing through deregulated 
translation, but we did not confirm strong synergy between Ibrutinib and CK1ε inhibitors, 
suggesting that the synergy that we observed was not due to MYC silencing but to PIK3CD 
inhibition184. Dual inhibition could explain why Umbralisib consistently presents potent cell 
line inhibition despite differing PI3K α/δ ratios. Our conclusions would best be evaluated 
in future xenograft mouse models, but the results from our ongoing clinical phase II clinical 
trial at UNMC should provide answers as well. Altogether, these results suggest a strong 
future for this combination, as well as future therapies that target these dual BCR signaling 
pathways, especially if safe dual PI3K α/δ inhibitors arise. 
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 After identifying the responsible factors of BCR inhibitor insensitivity, we sought to 
discover the cause of higher signaling. We accomplished this by pursuing the largest 
hypothesis-generating SCNA analysis of DLBCL to date. Our results pointed to TCF4 and 
its complex oncogenic transcription program as a key driver of aggressive DLBCL disease. 
Copy number gain at the TCF4 18q21 locus led to the promotion of essential BCR 
signaling components, most importantly the BCR heavy chain itself. More Ig surface 
molecules lead to increased levels signaling, crosslinking, and an inferior outcome. 
Targeted therapies aimed at transcription factors have not been successful in the clinic, 
so inhibition of TCF4 was a challenging prospect. However, TCF4 heavily relies on BRD4 
for expression, and there are epigenetic inhibitors available against this protein such as 
JQ1187,189. BRD4 inhibition was shown not only to abolish TCF4 but several of its key 
targets such as IgM surface molecules and BLNK, BTK, and PIK3CA, essentially crippling 
both key BCR pathways. The strong association between TCF4 copy number gain and 
PIK3CA upregulation levels points to another pivotal relationship worthy of exploration. 
Defining TCF4 gain cases with high PI3K α/δ ratios that are insensitive to PIK3CD 
inhibition would serve as a powerful diagnostic and clinical tool, but further work is 
warranted before making stronger conclusions, such as experiments specific to PTEN and 
PIK3CA when exposed to targeted therapies. Further work should include inducible TCF4-
KO for validation of our JQ1 observations, intracellular phosphoflow for TCF4, ChIP-Seq 
across several cell lines, and utilizing new CD79-GFP constructs capable of measuring 
surface immunoglobulin levels in real time. In particular, intracellular phosphoflow for BCR 
signaling in cell lines with TCF4-gain could be performed alongside the same cell lines 
after Doxycycline-inducible TCF4-KO. This experiment could validate the raw levels of 
BCR signaling owed to the presence of TCF4. Additionally, confirming TCF4-gain as a 
founder event or due to selective pressure later during lymphomagenesis through stage-
specific SCNA analysis would help define its role as genetic driver of disease. These future 
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experiments are especially important for the validation of further TCF4 targets that play a 
modulatory BCR signaling role. Abolishing these components through TCF4 inhibition is 
an exciting possibility for patients harboring 18q21 gains based on our results. 
BRD4 inhibitors alter the epigenetic landscape of DLBCL tumor cells, leading to 
cellular dysfunction and apoptosis, but careful attention will have to be paid to the 
emerging deregulations set off due to inhibition. Off-target effects will have to be carefully 
accounted for while this therapy is being evaluated. Moreover, the BRD4 inhibitor JQ1 has 
only been moderately successful in the clinic due to a short half-life and recurrent 
activation of the BCL2 oncogene266. Perhaps BRD4 inhibitors with greater efficacy in the 
clinic will open the door to a synergistic combination with the BCL2 inhibitor Venetoclax, 
but our preliminary results did not reveal strong synergy between the two compounds. 
One emerging therapeutic is the BRD4 PROTAC (proteolysis targeting chimera)192,193. 
This novel inhibitor eliminates BRD4 via proteasomal degradation and has the promise of 
an exciting new therapy capable of changing DLBCL treatment. 
The recent successes of CAR-T therapy in hematological malignancies represent 
an exciting paradigm shift, but this new treatment has provided a wealth of new 
challenges198. Handling a new set of patient symptoms, manufacturing turn-around times, 
and a lack of predictive factors designates a role for second-line therapies such as Ibrutinib 
and Umbralisib for the immediate treatment of refractory or relapsed DLBCL patients. Our 
results have defined BCR-proximal kinases and AKT signaling as a powerful new tool 
capable of identifying patients that would succeed with these therapies, especially in 
combination. One exciting possibility is the use of the combination for patients with 
aggressive disease that are waiting for CAR-T therapy manufacturing. This window of time 
is a key weakness of CAR-T treatment, but a fill-in therapy would only be possible after 
advances in lymphodepletion make it safe enough for maintenance treatment with BCR 
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inhibitors. The premier safety profile of Umbralisib could be particularly suited to this 
endeavor. 
 In conclusion, this dissertation has presented evidence to change how we 
categorize and treat aggressive cases of DLBCL, particularly the GCB-like subtype. We 
highlight the key, coordinated role of BCR-proximal and AKT signaling and the 
transcription factor TCF4 as its regulator. We suggest that these alterations may function 
in tandem to promote the expression and activity of BCR signaling components and that 
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Appendix: Ancillary Observations 
Activating BCR Signaling Pathway Mutations are not Reliable Determinants of Ibrutinib 
Sensitivity 
Next, previously reported results that BCR signaling mutations were another strong 
predictor of Ibrutinib sensitivity were investigated102,127,176. Utilizing Illumina next 
generation sequencing technologies, 34 of 39 available cell lines were sequenced to 
uncover mutations with the potential to predict Ibrutinib sensitivity. Stringent filters were 
applied to the annotated results, which considered minimum reads per length, maximum 
of bad reads, maximum ambiguous sequence characters, phred quality score, and a 
minimum depth of 100 reads. Alongside previously-designated “Triple-Hit” activating gene 
mutation drivers of DLBCL (BCL2, MYC, BCL6), Kyoto Encyclopedia of Genes and 
Genomes (KEGG)-designated BCR signaling pathway gene mutations were enriched in 





Patient samples with corresponding sequencing and COO subtype classifications 
reflected the cell line findings (Ancillary Figure 2). CARD11 mutations were more 
frequently observed in GCB-like patients than ABC-like patients (0.226 vs. 0.125). 
Conversely, MYD88 mutations were 10 times as likely to be observed in ABC-like patients 
as GCB-like counterparts were (0.335 vs. 0.034) but were not exclusive.  
 
Previous results reported that patients with CD79B mutations, and MYD88/CD79B 
double mutants were sensitive to Ibrutinib and that MYD88-only mutants were 
insensitive176. Four cell lines were confirmed to carry mutations of the MYD88 gene (HBL1, 
Oci-Ly3, SUDHL6, and TMD8) and two of these carried functional CD79B mutations in 
combination (HBL1 and TMD8). No significant difference in Ibrutinib sensitivity was 
detected between MYD88 WT and MYD88 mutant cell lines (P = 0.6761) (Ancillary Figure 
3). Similarly, 3/39 cell lines carried activating coiled-coil domain CARD11 mutations but 





Moreover, double CD79B/MYD88 mutants were predicted to be sensitive to Ibrutinib, but 
HBL1 was the most Ibrutinib-insensitive ABC-like cell line (ED50 = 7.751 PM). There was 
more than a 100-fold difference in Ibrutinib sensitivity between HBL1 and the other double 
MYD88/CD79B mutant, TMD8, as analyzed through two-way Analysis of variance 
(ANOVA) parametric analysis (P < 0.0001) (Ancillary Figure 4). Mean ED50 HBL1 and 
TMD8 values from three independent assays revealed a significant difference in 
sensitivity, despite the presence of similar BCR mutations and COO classification (P = 
0.0084) (Ancillary Figure 2). These results indicated that BCR signaling mutations were 





High PI3K α/δ Isoform Ratios are Associated with Umbralisib Insensitivity 
Recent work has highlighted the PIK3CA isoform as an opposing force to PIK3CD 
inhibitors in ABC-like DLBCL125,258. Tumors or cell lines capable of upregulating PIK3CA 
were observed to be less sensitive to the PIK3CD inhibitor Idelalisib. This relationship was 
observed through PIK3CA/PIK3CD (PI3Kα/PI3Kδ) ratio values, with higher ratios being 
less sensitive to PIK3CD inhibition125. Our collective Umbralisib ED50 sensitivity values of 
the U2932 (High PI3K α/δ), HBL1 (Medium PI3K α/δ), and TMD8 (Low PI3K α/δ) cell lines 
reflected this conclusion. U2932 was less sensitive to Umbralisib than HBL1 and TMD8, 
and HBL1 was less sensitive than TMD8 (Ancillary Figure 5). These results suggest that 
the PIK3CA isoform may play a role in Umbralisib response and augment insensitivity. 





Loss of PTEN is Associated with Increased NF-kB Activity 
PTEN and NF-kB activity were also opposed from one another, with PTEN-
deficient cell lines bearing greater NF-kB signaling levels (Ancillary Figure 6). This 
relationship proved to be narrowly insignificant (P = 0.0767). These results provided 
another link between the PI3K/AKT and BTK/BLNK/NF-kB signaling pathways that 




Cell Lines with TCF4 Gain are Equally Sensitive to BRD4 inhibition via JQ1 Treatment 
The TCF4 gain cell lines U2932 and RI-1 were assayed against JQ1 side by side 
and revealed a strikingly similar response with ED50 values of 89.9 nM and 123.1 nM, 
respectively (Ancillary Figure 7). Graphical quantifications of western blot results visualize 
TCF4 target reduction in response to JQ1 treatment (Ancillary Figure 8). Surface IgM 
reduction can be observed at smaller doses than those presented in the results section 
(Ancillary Figure 9). This can be visualized through bar graphs combining results from two 
independent experiments (Ancillary Figure 10). 
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